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Abstract
Behavioural testing in mouse models of Alzheimer’s disease (AD) suffers from lack of
standardization and reproducibility issues between laboratories. In order to solve this, a
touchscreen system has been developed for mice based on the Cambridge
Neuropsychological Test Automated Battery (CANTAB). There are several cognitive
dysfunctions that occur due to AD, including deficits in attention that can be tested using
the touchscreens. In this study, we tested two mouse models of familial AD (5xFAD and
3xTG) with mutations that lead to an accelerated rate of amyloidosis. Both male and
female mice were tested at two separate locations in order to test for the reproducibility
of results. Mice were tested as they aged (4.5, 7, 10 months) in order to establish when
cognitive symptoms first appear, with the 3xTG line showing deficits at 4.5 months and
the 5xFAD at 7 months. The results obtained between the two sites were not significantly
different for either line.
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Introduction

1.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting 35
million people worldwide (Organization, 2012). It is the most common cause of
dementia, accounting for 60-70% of all cases (Sy et al., 2011). AD affects 1 in 11 people
over the age of 65 in Canada and these numbers are expected to triple by the year 2050
(Herbert et al., 2014).
In ancient times, physicians from the Roman and Greek empires associated old age with
increased susceptibility to dementia (Berchtold and Cotman, 1998). In 1901, the German
physician and psychiatrist Alois Alzheimer identified the first case of AD in a fifty-year
old patient (Greenson, 1987). For most of the 20th century, it was difficult to distinguish
between dementia and AD, and the diagnosis of AD was reserved for patients exhibiting
symptoms between the ages of 45 and 65. In 1977, it was concluded that individuals of
any age that displayed the common characteristic symptoms, disease course and
neuropathology should be diagnosed with AD, independent of age (Boller and Forbes,
1998).
The earliest symptoms of AD include short-term memory loss followed by difficulty with
language, disorientation, and a variety of behavioural changes in motivation and mood
(Burns and Iliffe, 2009). As the disease progresses, there is more severe cognitive
decline, most notably episodic memory, as well as changes in sleep patterns and deficits
in motor functions (McDonald and Overmier, 1998). In addition, there is severe decline
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in executive functions; including working memory, sustained attention, task flexibility,
problem solving and reasoning (Monsell, 2003).
The pattern of cognitive decline in AD is believed to be the result of neuronal lesions that
may have been caused by amyloid-beta (Aβ) plaques and tau neurofibrillary tangles
(NFTs), leading to synaptic loss, and neuronal cell death (Gotz et al., 2004). In addition,
patients suffering with AD also have vascular lesions. It has been suggested that vascular
risk factors lead to the dysfunction of the blood-brain barrier and decreasing blood flow,
hence reducing the clearance of Aβ, leading to a cascade of events preceding dementia
(Zlokovic, 2011). Nevertheless, the presence of Aβ plaques and tau neurofibrillary
tangles (NFT) are considered to be the pathological hallmark of AD (Duyckaerts et al.,
2008).
The average life expectancy of individuals diagnosed with AD is eight to ten years with
fewer than 4% of people living longer than fourteen years (Molsa et al., 1986, 1995,
Zanetti et al., 2009). In 68% of all cases, the disease itself is the underlying cause of
death, usually due to pneumonia and dehydration (Molsa et al., 1986, Ganguli et al.,
2005).

1.2 Neuropathology of AD
AD is characterized by loss of neurons and synapses in the cerebral cortex and different
subcortical regions. It is believed that Aβ plaques and NFTs lead to degeneration of
neurons in the parietal and temporal lobes as well as parts of the frontal cortex (Wenk,
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2003). Both Aβ plaques and NFTs are clearly visible under microscopy of brains of
people with AD (Tiraboschi et al., 2004).
Amyloid plaques are dense, mostly insoluble deposits of amyloid-beta (Aβ40 and Aβ42)
peptides and cellular material outside of neurons (Tiraboschi et al., 2004). Aβ peptides
are fragments of the larger amyloid precursor protein (APP), a neuronal transmembrane
protein critical to neuron survival, growth, and post-injury repair (Priller et al., 2006).
APP is cleaved by the activity of three proteolytic enzymes: alpha, beta, and gamma
secretases, however only the latter two give rise to the toxic Aβ peptides (Hartmann et al.,
1997). The Aβ peptides are excised from the larger APP holoprotein through sequential
scission by the β-APP cleaving enzyme (BACE) and the gamma secretase enzymatic
complex (Yan et al., 1999).
Mutations in presenilin-1 (PSEN1) and presenilin-2 (PSEN2), proteins that form the
catalytic domain of the larger gamma secretase complex (De Strooper et al., 1999,
Hooper, 2005) lead to AD. Gamma secretase cleaves within the transmembrane domain
of APP and produces the C-terminal end of Aβ (Hartmann et al., 1997). Aβ peptides are
known to aggregate to form soluble Aβ oligomers in the extracellular environment and
these have been shown to be the most toxic form of Aβ (Zhao et al., 2012). In AD, Aβ
oligomers accumulate and form fibrils which further form clumps around neurons leading
to dense insoluble formations known as senile plaques (Ohnishi and Takano, 2004,
Tiraboschi et al., 2004). Plaque deposition normally begins in the basal portions of the
neocortex, followed by the hippocampus and eventually spreading to subcortical areas
over time (Braak and Braak, 1991).
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The second hallmark of AD, NFTs, is caused by the abnormal hyperphosphorylation and
misfolding of the protein tau (Bouras et al., 1994). Tau is a microtubule-associated
protein (MAP) that is a major component of a group of MAPs that stabilize microtubules
and induce its own assembly (Maccioni and Cambiazo, 1995). Microtubules act like
tracks, guiding nutrients from the cell body to the ends of axons and back. However,
under pathological conditions, tau becomes hyperphosphorylated causing it to selfaggregate into paired helical filaments, which eventually aggregate to create the
neurofibrillary tangles in the intracellular environment (Berger et al., 2007). The
microtubules are the cytoskeleton for axons and their collapse leads to the disintegration
of the neuron’s transport system (Hernandez and Avila, 2007).
Although amyloid plaques and NFTs are associated with AD, it is still not clear how they
give rise to the neurodegeneration associated with the disease (Huang and Mucke, 2012).
As discussed in detail in the next section, the amyloid hypothesis points towards the
accumulation of Aβ peptides as the central event triggering neuronal degeneration. Toxic
amyloid oligomers disrupt neuronal signaling leading to aberrant calcium ion
homeostasis and apoptosis (Yankner et al., 1990). In addition, it has been suggested that
long before the development of senile plaques, Aβ oligomers attach onto the synapse of
neurons disrupting cell-to-cell communication (Lacor et al., 2007, Zhao et al., 2012). The
tau hypothesis on the other hand, points towards hyperphosphorylated tau protein as the
trigger that leads to degeneration of neurons and eventually cell death (Gray et al., 1987).
Normally, organelles are transported to and from the cell body of a neuron through the
axon and dendrites, which has a skeleton composed of microtubules (Maccioni and
Cambiazo, 1995). Microtubules are stabilized by the tau protein, however in AD, tau
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becomes hyperphosphorylated and detaches from the microtubules (Iqbal et al., 2005).
Thus, the skeleton of the neuron dissociates and the defective tau protein form filaments
that eventually generate the NFTs. Without the microtubule skeleton, and with the
accumulation of NFTs, neurons degenerate and connections between the neurons are lost.
This eventually causes the death of the neuron (Chun and Johnson, 2007, Hernandez and
Avila, 2007). NFTs first develop in the hippocampus, which is essential to memory and
learning and then spreads to the whole brain in a centrifugal movement causing atrophy.
The progression of AD symptoms follows the pattern of NFT lesions (Iqbal et al., 2005).

1.3 Genetic Underpinnings of AD
The cause of most AD cases is unknown except for the cases where genetic mutations
have been identified. Hence, AD can be classified as two main sub-types: sporadic onset
AD and familial AD (FAD). Only about 1% to 5% of patients afflicted with the disease
have the FAD form, whereas the other 95% to 99% have sporadic onset AD (Delacourt et
al., 2002). Based on family and twin studies, the genetic heritability of AD range from
49% to 78% and around only 0.1% of familial cases of AD are early onset meaning they
occur before the age of 65 (Wilson et al., 2011).
The genetic basis for sporadic onset AD is not well understood. Overall, there are many
different risk factors that seem to lead to the sporadic form of AD and the genetic
underpinnings that underlie this form of AD are not immediately obvious. The bestknown genetic risk factor is the inheritance of the ε4 allele of the apolipoprotein E gene
(APOEε4), and between 40% to 80% of people with AD present at least one APOEε4
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allele (Strittmatter et al., 1993, Mahley et al., 2006). In addition, the APOEε4 allele
triples the risk of AD in heterozygotes and increases it by 15 times in homozygotes
(Blennow et al., 2006). Apolipoproteins have been shown to enhance the breakdown of
Aβ, however the APOEε4 isoform is not very effective at doing so leading to a build-up
of Aβ peptides (Polvikoski et al., 1995). Although the APOEε4 allele has been shown to
increase susceptibility to develop AD, not all individuals with the gene develop the
disease, and many individuals without the allele develop AD (Selkoe, 2012). For
example, a study conducted in Nigeria showed no relationship between the APOEε4 and
onset of AD (Hall et al., 2006). In addition to the APOEε4 allele, there are 19 other
genetic loci that have been identified to significantly increase the risk of developing AD
(Lambert et al., 2013). A meta-analysis of genome-wide association study (GWAS)
conducted by Lambert et. al. in 2013 identified 11 of these genetic loci that increase the
susceptibility of late-onset AD (Lambert et al., 2013). One of these loci was SORL1, a
neuronal APOE receptor involved in regulating APP. SORL1 was found to have reduced
expression in AD (Scherzer et al., 2004). Other loci identified include PTK2β, an enzyme
important for calcium-induced regulation of neuronal ion channels and activation of the
map kinase pathway; FERMT2, a protein that is a component of extracellular matrix
structures required for control of cell shape; and CLU, a protein associated with the
clearance of cellular debris and apoptosis (Lev et al., 1995, Jones and Jomary, 2002, Tu
et al., 2003). In addition, mutations in the triggering receptor expressed on myeloid cells
2 (TREM2) have also been shown to be associated with a 3-5 times increased risk of AD.
It has been suggested that due to the TREM2 mutation, microglia cells are no longer able
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to control the amount of Aβ peptides present in the brain (Guerreiro et al., 2013, Jonsson
et al., 2013).
In contrast, FAD is better understood and the genes involved have been identified and
isolated. Most cases of FAD can be attributed to missense mutations in at least one the
following three genes: APP, PSEN1 or PSEN2 (Waring and Rosenberg, 2008). There
have been more than 50 different APP mutations identified, the most common of which is
the V717I, which replaces the amino acid valine with the amino acid isoleucine at protein
position 717 (Eckman et al., 1997). The PSEN1 gene, found on chromosome 14, is the
most common cause of FAD with over 150 different identified mutations. The PSEN1
gene encodes for the presenilin-1 protein part of the gamma secretase complex (De
Strooper, 2007). PSEN1 mutations lead to an altered protein that becomes inactive and
causes gamma secretase to cleave at a different location releasing the longer toxic
peptides of Aβ (Zahs and Ashe, 2015). These mutations increase the production of toxic
Aβ peptides that are 42 amino acids in length (Aβ42), and have been shown to be the
main component of senile plaques. However, a recent study showed mice that are
homozygous for PSEN1 mutations have complete loss of function of gamma secretase
and die during the embryonic stage. Mice carrying more than one PSEN1 mutation had a
decreased production of Aβ, but an increased ratio of Aβ42/Aβ40 that exacerbated Aβ
deposition (Xia et al., 2015). The ratio of Aβ42/Aβ40 has been previously proposed to
have important ramifications in the onset of plaques observed in AD, rather than the
amount of Aβ42 alone (Jarrett et al., 1993).
One of the most well known mutations of AD is the Swedish FAD mutation occurring on
the APP gene, originally discovered in 1992 (Mullan et al., 1992). Carriers of this
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mutation will pass it on to 50% of their offspring who will go on to develop early onset
AD. This mutation however is extremely rare, only found in two Swedish families and
never in the general population (Mullan et al., 1992). Similarly the Florida FAD mutation
was observed in an individual from Florida who had a family history of dementia with an
average onset of 53 years. Once the mutation was expressed in cell cultures it led to a
three-fold increase in Aβ42 (Eckman et al., 1997). The London FAD mutation was
discovered in 1991 in England and was the first described mutation of APP. This
missense mutation also increases the levels of Aβ42 in many cell types that leads to early
onset AD (57 years of age approx.) (Goate et al., 1991).
On the other hand NFTs, the secondary hallmark of AD, caused by the accumulation of
hyperphosphorylated tau protein, lack genetic evidence linking any FAD tau mutations to
the onset of the disease (Selkoe, 2011). As a matter of fact, disorders involving a tau gene
mutation have shown that the development of NFTs alone does not lead to the
development of Aβ plaques. Hence, it has been suggested that Aβ peptides can lead to the
development of NFTs, but tangles do not lead to the development of Aβ peptides (Selkoe,
2011).

1.4 The Amyloid Hypothesis of AD
The amyloid hypothesis was first introduced in 1991 and builds on the knowledge of the
genetics of FAD postulating that accumulation of amyloid plaques are the fundamental
cause for the disease (Hardy and Allsop, 1991). It postulates that Aβ, in a variety of
forms, triggers a cascade of events that harm synapses and neurons, producing the
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pathological hallmarks of plaques, NFTs, synapse loss and neurodegeneration, that leads
to dementia (Hardy and Selkoe, 2002). One aspect of the hypothesis suggests that there is
a build-up of soluble Aβ oligomers due to the activity of β-secretase and gamma
secretase on APP, which leads to the insoluble senile plaques (Yan et al., 1999). Some
researchers have postulated that toxic Aβ oligomers, referred to as amyloid-derived
diffusible ligands (ADDLs), may be the primary pathogenic form of Aβ. These ADDLs
bind to neuronal surface receptors and alter the structure of the synapse disrupting cell-tocell communication (Lambert et al., 1998, Lacor et al., 2007). The hypothesis is
supported by the location of the APP gene on chromosome 21. Individuals with an extra
copy of this chromosome (trisomy 21 – down syndrome) universally exhibit AD by the
age of 40 (Lott and Head, 2005).

1.5 The Cholinergic Hypothesis of AD
The cholinergic hypothesis is the oldest postulation of AD. It proposes that AD is caused
by reduced synthesis of the neurotransmitter acetylcholine (ACh) due to substantial
deficits in the enzyme responsible for making ACh, choline acetyltransferase (ChAT)
(Bowen et al., 1976, Davies and Maloney, 1976, Perry et al., 1977). Subsequent
discoveries of reduced choline uptake, ACh release, and loss of cholinergic neurons in
the basal forebrain, confirmed a substantial presynaptic cholinergic deficit in AD
(Whitehouse et al., 1982, Rylett et al., 1983, Nilsson et al., 1986). In addition, at the time,
research also showed the importance of ACh for cognitive function, such as learning and
memory (Drachman and Leavitt, 1974). Further support for the hypothesis was provided
by studies showing strong correlations between the deterioration of the basal forebrain
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cholinergic system and the occurrence of senile Aβ plaques (Perry et al., 1978, Wilcock
et al., 1982). However, during the last 20 years, the cholinergic hypothesis has not
maintained widespread support, mainly because pharmacological interventions intended
to treat acetylcholine deficiency, seen in AD, have not been very effective (Francis et al.,
1999).

1.6 Current Pharmacological Interventions for AD
There is no cure for AD, and current pharmacological treatments help delay symptoms
and maintain cognition for a short period of time. Despite considerable advances in
knowledge regarding the pathogenesis of AD, no concrete treatments have been
introduced over the past 25 years (Schneider et al., 2014). There are only five drugs that
have been marketed for the treatment of AD: four acetylcholinesterase inhibitors (tacrine,
rivastigmine, donepezil and galantamine), and the NMDA receptor antagonist memantine
(Schneider et al., 2014). There is a reduction in the release of ACh in AD (Perry et al.,
1977). Acetylcholinesterase inhibitors block the activity of acetylcholinesterase, an
enzyme found in the synaptic cleft responsible for breaking down ACh, thereby
increasing the concentration of this neurotransmitter in the brain (Massoulie et al., 1993).
Evidence suggests that the acetylcholinesterase inhibitors approved for treatment seem to
have efficacy only in mild to moderate AD and not during the advanced stages of the
disease (Birks, 2006, Schneider et al., 2014). Therefore, these drugs are only beneficial in
temporarily delaying the onset of cognitive deficits associated with AD.
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A review published in 2008 identified 100 AD drug development failures in clinical trials
(Becker et al., 2008). In the last two decades (since 1991), the focus of AD drug
development has been on the amyloid hypothesis and the toxic Aβ found in the brain.
The majority of drugs that were developed for AD attempted to disrupt the activity of the
proteases, β-secretase and gamma secretase, however none have been successful in
clinical trials (Becker et al., 2008). Although in theory the amyloid drugs seem simple,
either by reducing its production through inactivating the enzymes that produce it or by
increasing its clearance out of the brain, it has been quite complex to implement it in
practice. One reason for the failure of this approach may be due to differing toxicities of
various Aβ components. For example, oligomers have been found to be toxic at the
synapse and Aβ fibrils from plaques may be pro-inflammatory leading neurotoxicity in
their local environment (Mucke and Selkoe, 2012). Hence, it is unclear whether
inhibition of Aβ fibril aggregation, inhibition of APP secretases, or antibodies against the
different forms of Aβ are valid therapeutic strategies (Schneider et al., 2014).

1.7 Development of AD Mouse Models
As with other slowly progressive diseases, preventing AD depends on understanding the
early steps in its pathogenesis. For this reason, considerable time and efforts has been
invested in the development of animal models for AD. Although it accounts for only a
small portion of AD patients, identifying gene mutations involved with the FAD form of
the disease greatly enhanced Alzheimer’s research (Selkoe, 2012). Researchers were able
to create transgenic mice that had the FAD mutations in APP and presenilins that lead to
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the expression of Aβ plaques similar to those seen in humans (Gotz et al., 2004,
Schnabel, 2011).
One of the first AD mouse models generated was the Tg2576 that had the APPSWE FAD
mutation (Hsiao et al., 1996). The Tg2576 mice showed deficits in spatial working
memory at 5 months of age in one study, however different methodologies used in
several other reports failed to reproduce these results (Hsiao et al., 1996, Arendash et al.,
2004). Studies have also shown the Tg2576 mice to have deficits in recognition memory
at 12 months of age (Oules et al., 2012).
Another important mouse model of AD was the APP/PS1 mice that had both the APPSWE
mutation as well as a mutation on PSEN1 that lead to Aβ plaques (Holcomb et al., 1998).
The first reported deficits in spatial working memory were 6 months of age in the
APP/PS1 mice, however these were not robust and other reports have failed to reproduce
these data (Holcomb et al., 1999, Arendash et al., 2001a). Consistent deficits in working
memory have been reported in the APP/PS1 mice at 15 months of age and deficits in
recognition memory at 12 months of age (Arendash et al., 2001b, Mori et al., 2013).
Hence, most of the early mouse models of AD focused on developing the Aβ plaques
pathology and demonstrated robust cognitive deficits in the later stages of the animal’s
life. In this thesis we will focus on two models of AD described below that either present
plaques and NFTs or have high rates of amyloidosis (aggregation of Aβ) and plaque
formation.
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1.8 The 3xTG Mouse Model of AD
In 2003, Oddo et al. developed a mouse model of AD that exhibited both Aβ plaques as
well as tau NFTs called the triple transgenic mouse (3xTG). These mice possess the
Swedish FAD mutation of APP (APPSWE) as well as a mutation on the presenilin-1
(PSEN1M146V). In addition, the 3xTG mouse line also has a point mutation on a tau
transgene (tauP301L) that gives rise to hyperphosphorylated tau protein leading to the
development of NFTs (Oddo et al., 2003b). The 3xTG mouse line was generated by
microinjecting the human APPSWE and tauP301L transgenes into the germline of PS1M146V
knock-in mice. The result was a mouse model that expressed both plaques and tangles
that increased in severity with age (Oddo et al., 2003b). 3xTG mice express Aβ plaques
and NFTs in analogous brain regions to that seen in human AD patients, and progression
of pathology also follows similar patterns to that seen in humans, with plaque deposition
preceding the development of visible NFTs (Oddo et al., 2003b, Sy et al., 2011).
The 3xTG mice show no Aβ plaques or NFTs at two months of age (Oddo et al., 2003b).
However, at this age, other researchers have shown the 3xTG mice to have axonal myelin
sheath deterioration in the Schaffer Collateral pathway projecting from the hippocampus
(Desai et al., 2009). The appearance of Aβ pathology occurs first in the neocortex at four
months of age, however most of the Aβ is in its soluble form at this stage and has not
started to develop into plaques. At 6 months of age, intraneuronal Aβ is detectable in both
the amygdala and hippocampal neurons (Oddo et al., 2006a). At approximately 9 months
of age, there is a decrease in intraneuronal Aβ that is coincident with the development of
extracellular Aβ plaques in the cortex. These extracellular plaques increase in both size
and number exponentially with age and by 12-15 months the 3xTG mice show significant
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Aβ plaques in both the hippocampus and cortex (Oddo et al., 2003b, Oddo et al., 2006a,
Sy et al., 2011).
Similarly, AD-like tau pathology also progresses with age in the 3xTG mice.
Hyperphosphorylated tau protein can first be detected in the CA1 pyramidal neurons of
the hippocampus at 6 months of age (Oddo et al., 2003a). Levels of abnormally
phosphorylated tau continue to increase in the hippocampus and by 9 months of age are
also detectable in the cortex. By the time mice are 10 months of age,
hyperphosphorylated tau aggregates to form NFTs in both the cortex and hippocampus.
The density of these NFTs continues to increases exponentially as mice age (Oddo et al.,
2003a, Oddo et al., 2003b).
The 3xTG mice have been shown to have cognitive deficits in various behavioural
studies. The 3xTG mice were tested at 2 months of age on the Morris Water maze task
but showed no deficits (Clinton et al., 2007). However, in a separate study conducted
using the 8-arm radial maze task to test for working memory, the 3xTG mice did show
deficits starting at 2 months and onwards until the age of 15 months (Stevens and Brown,
2015). The first deficits observed in associative learning occur between the age of 3 and 5
months (Clinton et al., 2007). These are then followed by deficits in spatial working
memory using the Morris Water Maze task at 6 months of age (Billings et al., 2005,
Nelson et al., 2007). Deficits in recognition memory have been observed between 9-11
months of age (Billings et al., 2005, Clinton et al., 2007, Nelson et al., 2007). Also,
impairments in reference memory were observed in the 3xTG mice using the Barnes
Maze task at 12 months of age (Nelson et al., 2007). In addition, as discussed in greater
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detail in the next section, 3xTG males showed deficits in sustained attention when tested
using touchscreen systems at 10 months of age (Romberg et al., 2011).
Interestingly, a recent study showed that short-term stress induced a decrease in the
number of synaptic dendritic spines and increased the levels of Aβ in 3xTG mice, hence
accelerating amyloid pathology (Baglietto-Vargas et al., 2015). Additionally, it has been
shown that cholinergic modulation of hippocampal synaptic plasticity is impaired due to
the PSEN1 mutation in 3xTG mice (Wang et al., 2009). In summary, the neuropathology
of AD-like plaques and tangles as well as the AD-like cognitive deficits strengthens the
face validity of the 3xTG as a mouse model of AD.

1.9 The 5xFAD Mouse Model of AD
Most mouse models of AD, including the above mentioned 3xTG mice, develop
neuropathological and significant behavioural deficits in the latter stages of life. Although
this increases the face validity of these mouse models since they recapitulate the late
onset of AD as seen in humans, it proposes other technical disadvantages such as high
housing costs for animal facilities, and long delays between planning and performing
experiments (Bilkei-Gorzo, 2014). For these reasons, a new transgenic mouse line was
developed by Oakley et al. in 2006 bearing five FAD mutations called the 5xFAD mice,
that developed AD-like pathology at a much younger age (Oakley et al., 2006). The
5xFAD mice have three FAD mutations on the APP transgene with the Swedish
(APPSWE), Florida (APPFL) and London (APPLON) mutations, and two FAD mutations on
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the presenelin-1 transgene (M146L and L286V). These mutations were introduced into
mice using the neuron specific Thy1 promoter (Oakley et al., 2006).
Together, all five of these FAD mutations lead to an accelerated rate of intracellular
amyloidosis starting at just 1.5 months of age and extracellular Aβ plaques are present at
2 months in this mouse model. Aβ plaques first appear in layer 5 of the cortex and the
subiculum at 2 months of age, and spread rapidly to fill the rest of the cortex, subiculum
and hippocampus by 6 months (Oakley et al., 2006). Due to this rapid amyloidosis, by 9
months of age, the 5xFAD mice have significant synaptic degeneration and neuron loss
(Oakley et al., 2006, Bilkei-Gorzo, 2014).
Multiple studies have observed progressive cognitive deficits with age in the 5xFAD
mice. This model shows deficits in spatial working memory using the Morris Water Maze
by 3 months of age (Ohno et al., 2006, Urano and Tohda, 2010). In a study used to test
for hippocampal-dependent memory deficits using the olfactory tubing maze, 5xFAD
mice showed deficits beginning at 4 months of age and the deficits increased significantly
by 6 months (Girard et al., 2014). 5xFAD mice also showed hippocampal-dependent
spatial working memory deficits when tested using the Y-maze task at 4 months of age
but not at an age of 2 months (Oakley et al., 2006). Additionally, 5xFAD mice showed
impairments in associative learning, in fear conditioning, as well as deficits in working
memory using the Y-maze task (Oakley et al., 2006, Ohno et al., 2006). As seen in 3xTG
mice, cognitive deficits in recognition memory are observed last in the 5xFAD mice - at
10 months of age (Tohda et al., 2012). In summary, although 5xFAD mice do not exhibit
tau NFT pathology like 3xTG mice, they do have an accelerated rate of amyloidosis
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leading to extensive Aβ plaques and neurodegeneration that contributes to the various
AD-like cognitive deficits observed.

1.10 Attention Deficits in AD
Attention is the first non-memory domain affected in AD, before deficits in visuo-spatial
function and language. It is believed that attention deficits are responsible for the
difficulties with daily living for patients in the early stages of AD (Bracco et al., 2014).
Lesion studies in mice have revealed multiple forebrain regions, such as the medial
prefrontal cortex, anterior cingulate cortex and the parietal cortex, to be essential in
choice accuracy for mice (Muir et al., 1996). Brain correlates for attention in humans has
been shown to be in similar regions, mainly the frontal and parietal cortices (Pepeu et al.,
2013). In terms of neurotransmitter systems involved in attentional control, major
findings over a 20-year period, have shown selective lesions in the monoaminergic
(noradrenergic, dopaminergic and serotoninergic) and cholinergic systems to cause the
greatest deficits (Robbins, 1997, Pepeu et al., 2013). Since arousal and attention depend
on activation of the forebrain cholinergic system, it is to be expected that the loss of
cholinergic neurons occurring in AD may lead to impairment of the attentional processes
(Pepeu et al., 2013). Improvement of attention following cholinesterase inhibitors, such
as donepezil, administration has been demonstrated in mouse models of AD (Romberg et
al., 2011). In addition, cholinesterase inhibitors have been shown to improve global
cognitive measures in AD and attenuate the neuropsychiatric symptoms through a
primary effect on the cholinergic neurons involved in regulating attention (McGuinness
et al., 2010, Pepeu et al., 2013).
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1.11 CANTAB Touchscreen Systems
Despite over thirty years of research on AD and numerous potential treatments that were
tested in clinical trials, there have been no drugs that have been able to halt or reverse the
progression of the disease (Selkoe, 2012, Schneider et al., 2014). There have been many
pharmacological interventions that have shown promise in pre-clinical animal studies of
AD, but have failed to translate the same results in the clinic (Schneider et al., 2014). One
critical issue that has been identified for this lack of translatability is the difference
between tests of cognition used for mice in pre-clinical research and those used in
humans with AD (Romberg et al., 2013a). The Cambridge Neuropsychological Test
Automated Battery (CANTAB) has been used to assess cognitive dysfunctions in
neuropsychiatric and neurodegenerative disorders including AD and mild cognitive
impairment (Junkkila et al., 2012). Based on the CANTAB battery, a touchscreen system
has been developed by Tim Bussey, Lisa Saksida and colleagues, to make behavioural
cognitive tests in rodents more standardized, automated and increase the translational
potential of research in mouse models (Bussey et al., 2008).
The first advantage of using the touchscreen systems to test for cognitive deficits in mice
is that they are automated. Having an automated behavioural test reduces the amount of
labour required and allows researchers to test multiple mice simultaneously. Moreover,
an automated behavioural test such as these touchscreens allows researchers to
profoundly reduce the interaction between animals and the experimenter eliminating
confounds that this interference might entail during testing (Bussey et al., 2012). Human
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interference during behavioural testing can have huge effects, not only by introducing
variability in the way the test is run, but also by potential confounds in the way each
experimenter handles the animals, or even the sight and smell of the experimenter
(Wahlsten et al., 2003). In addition, since a computer controls the touchscreen systems,
many parameters including stimulus presentation and delays are identical every time for
each animal and all measures of the test are then collected by the computer making it
possible to collect data down to the exact millisecond (Bussey et al., 2012). The use of a
computer-controlled system also allows for the collection of multiple parameters at once
such as accuracy, omissions, and latencies to name a few. Overall, due to their
automation, the touchscreen systems might be more reliable than non-automated
behavioural tests such as mazes.
The second advantage of using touchscreen systems is that they cause low stress to the
animals. It is important to avoid unnecessary stress when testing for cognitive deficits in
diseases such as AD. The touchscreen systems used in this study are reward based, rather
than aversive thus reducing the amount of stress an animal might encounter (Bussey et
al., 2012).
Finally, the main advantage of using touchscreen systems is their translatability. By
creating the same tasks for mice as the CANTAB, researchers can test for the same
cognitive domains that are tested in humans with AD and other mild cognitive disorders
(Bussey et al., 2012). Currently the tests used in animals, such as the Morris water maze,
are usually nothing like those we use in clinical populations; i.e. humans who are old and
might be suffering from AD do not have their working memory tested in a swimming
pool with a hidden platform like mice tested in the Morris water maze task. This creates a
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huge disconnect when promising results found in animal research do not translate into the
same outcomes in the clinic (Bussey et al., 2012). By using the touchscreen systems that
are as similar as possible to human tests, this study aims to increase the face validity of
behavioural testing and increase the translational effectiveness of future studies in the
clinic.
The touchscreen systems can be used in various different rodent tasks to test for deficits
in learning and memory, executive function, working memory, and pattern separation.
For learning and memory, there are a number of different tasks that can be used on the
touchscreen systems. The visual discrimination (PD) task is relatively simple and used to
test whether animals can distinguish between two different stimuli with one being the
conditioned stimulus (CS+) that is rewarded compared to the second stimulus (CS-)
(Horner et al., 2013). In the paired-associate learning (PAL) task, the correct stimulus is
identified by the combination of the stimulus itself and spatial location on the screen
(Horner et al., 2013). The visuomotor conditional learning (VMCL) task requires the
animal to identify the conditional visual stimulus that is presented and answer correctly
(left or right) (Horner et al., 2013).
For testing executive functions, Bussey and his colleagues have described several other
tasks that can be utilized on the touchscreen systems. First, extinction learning can be
used to assess the rate and extent of curtailing a stimulus that was previously associated
with a reward but no longer is (Mar et al., 2013). Secondly, reversal learning can be
testing using the PD task by switching the CS+ stimulus with the CS- stimulus and
measuring the rate it takes an animal to extinguish the initial task and learn the new one
(Mar et al., 2013).
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Lastly, the 5-Choice Serial Reaction Time Task (5-CSRTT) can be used in order to test
for the ability of an animal to selectively detect and respond to spatially unpredictable
visual stimuli (Mar et al., 2013). The original development of the 5-CSRTT was based on
the continuous performance test designed by Rosvold and Mirsky in a nine-hole operant
chamber, used to test sustained and divided attention (Beck et al., 1956). Many early
attempts to examine attention control in animals used this nine-hole box (Carli et al.,
1983). Rodents had to monitor the occurrence of a brief target stimulus (light) in one of
five holes at the back of the box, detected by a nose-poke response monitored by infrared
photocell beams, and correct responses rewarded by a food pellet in the magazine tray at
the rear of the chamber (Robbins, 2002). The task was essentially designed to test the
ability of the rodent to sustain spatial attention divided amongst a number of locations
over a number of trials and this is measured by the accuracy of the total number of
correct trails (Robbins, 2002). Difficulty in the 5-CSRTT can be varied by adjusting the
brightness of the stimuli, adding distracting stimuli such as bursts of white noise or
presenting visual stimuli in locations not associated with the test (Robbins, 2002). The 5CSRTT used in the present study utilized the Bussey touchscreen chambers to present
rodents with 5 spatial locations on a screen in order to test attentional demand at various
stimulus lengths (Mar et al., 2013).

1.12 Objectives of this Study
Hypothesis: Attention deficits are common behavioral abnormalities in mouse models of
AD. The 3xTG and 5xFAD mouse models will both show attentional deficits using the 5-
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CSRTT. The appearance of the phenotype will vary depending on the severity of AD
pathology for each model.
Rationale: Attentional control, part of the overall executive functions, declines during the
early stages of AD (Baddeley et al., 2001). Like memory, attention is controlled by
multiple cortical and subcortical regions in the brain (Duncan, 2006). Although AD is
most commonly known as a memory disorder due to the loss in episodic memory, deficits
in sustained attention and executive functions occur earlier in the disease and are usually
overlooked by patients (Artero and Ritchie, 2003). The deficits in executive control
(including attention) precede impairments in language, spatial and long-term memory
(Bentley et al., 2008). Hence, understanding the nature of attention deficits that occur
early in AD may provide insights into the mechanism and lead to potential
pharmaceutical interventions that can be applied before the disease further advances.
Aim 1: The first aim was to test the 3xTG and 5xFAD mouse models of AD for attention
deficits as they age, using the 5-CSRTT. Multiple cognitive domains are compromised in
AD. Deficits in executive functioning and sustained attention occur during the early
stages of AD (Romberg et al., 2013a). Understanding the characteristics of attention
deficits in AD can help detect the disease during its early stages before it progresses. The
3xTG and 5xFAD mouse lines were selected for this study as they have the fastest
progression of AD-like pathology and cognitive symptoms and would be ideal candidates
for future studies in order to test for potential therapeutic interventions. In this study, we
proposed to determine if and when each mouse line develops deficits in sustained
attention. Male 3xTG mice were previously tested using the 5-CSRTT by Romberg et. al.
in 2011 and were shown to have deficits at 10 months of age (Romberg et al., 2011).
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However, as mentioned above, the 3xTG mice develop plaques and tangles earlier and
have shown to have cognitive deficits between 3-5 months of age (Clinton et al., 2007).
In addition, the 5xFAD mice have been shown to have Aβ plaques at 2 months of age and
working memory deficits present at 3 months of age (Oakley et al., 2006, Ohno et al.,
2006, Urano and Tohda, 2010). Hence, in this longitudinal study, both mouse lines were
tested multiple times on the 5-CSRTT as they aged (4.5, 7, 10 months) in order determine
when attention deficits first appear and whether these deficits get progressively worse
with age.
Aim 2: The second aim of this study was to determine whether data are reproducible
when the 5-CSRTT is run at two different sites. Traditional cognitive behavioural testing
in mouse models is subject to extreme variation (Wahlsten et al., 2003). There are
multiple reasons as to why this occurs including the use of distinct protocols used by
different labs, and experimenter error or bias due to lack of automation (Landis et al.,
2012, Button et al., 2013). The touchscreen systems used in this study were designed to
overcome these impediments. Reproducibility of data is key in cementing the touchscreen
systems as a valid behavioural paradigm in order to determine cognitive deficits in mice.
However, this has not yet been tested systematically. Thus, this study tested both the
3xTG and 5xFAD mice at the University of Western Ontario and at Dr. Boyer Winters’
laboratory at the University of Guelph simultaneously (experiments conducted by Daniel
Palmer).
Aim 3: The last aim of this study was to determine whether there are sex differences in
the 3xTG and 5xFAD mouse models of AD. For humans, almost two-thirds of
individuals

affected

with

the

disease
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are

women,

suggesting

females

are

disproportionately affected by AD (Bennett, 2007). The primary explanation for this is
due to the fact that women live longer and AD occurs during the latter stages of life
(Seshadri et al., 1997, Bennett, 2007). However, many age-specific studies conducted
have not been able to find any significant conclusions that age is the reason why women
have a higher prevalence for AD (Seshadri et al., 1997, Hebert et al., 2001). Hence, there
is no evidence that women are more likely to develop AD than men at any given age.
Thus, the study conducted here tested both male and female mice for the 3xTG and
5xFAD mice in order to determine whether there is any difference in the onset and
progression of cognitive deficits. To the best of my knowledge, this is the first time
female mice were tested on the touchscreen systems.
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2

Materials and Methods

2.1 3xTG Mice
The 3xTG mice (B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa) and age-matched
control mice (B6129SF2/J) used in this study were all bred at the Jackson Laboratory in
Bar Harbor, Maine, and shipped to Canada for behavioural testing. In summary, the
3xTG mice were homozygous for three mutations (PSEN1, APPSWE, and tauP301L) (Oddo
et al., 2003b). The wild-type control mice were generated by crossing C57BL/6J females
(B6) and 129S1/SvImJ males (129S) in order to create the B6129SF2/J mice.
The mice used in the present study, twelve 3xTG males, twelve 3xTG females, twelve
B6129SF2/J wild-type control males and twelve B6129SF2/J wild-type control females,
were three months of age at the start of behavioural testing. At this age 3xTG mice
exhibit few or no extracellular Aβ deposits and relatively low levels of
hyperphosphorylated tau (Nelson et al., 2007, Hirata-Fukae et al., 2008).

2.2 5xFAD Mice
The 5xFAD mice (B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/J) and
age-matched wild-type controls (B6SJLF1/J) were also bred at the Jackson Laboratory in
Bar Harbor, Maine, and shipped to Canada for behavioural testing. The mice used in the
present study, twelve 5xFAD males, twelve 5xFAD females, twelve B6SJLF1/J wildtype control males, and twelve B6SJLF1/J wild-type females, were three months of age at
the start of behavioural testing. The 5xFAD mice have previously demonstrated to have
intraneuronal Aβ present starting at 1.5 months of age (Oakley et al., 2006).
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2.3 Housing and Food Restriction
Mice of the same genotype and sex were housed in groups of 2, in a room with a 12-hour
light/dark cycle (lights turn off at 7:00 P.M.). All behavioural testing was conducted
during the light phase of the cycle. Mice were maintained on a restricted diet and kept at
85% of adult baseline body weight during the experiment. This was done in order to
ensure the animals were motivated to perform the behavioural touchscreen tasks. All
mice were put on food restriction one week prior to the start of behavioural testing and
the body weights were gradually lowered to 85% of the original weight.
To determine the weight curve of a typical mouse as it ages, mouse weights of wild-type
mice at various ages, ranging from pups to adult mice were recorded (Figure 1). Based
on these weight curves for both male and female mice (Figure 1), we determined the
ideal 85% body weight for males should be 23.0 grams and females 20.0 grams, at the
start of behavioural training. Once body weight was reduced to 85% of baseline for an
individual mouse, it was safely maintained throughout the testing period by providing
2.5g of food per day for males and 2.0g of food per day for females (Tekland Chow –
Harlan). Mice were weighed every other day in order to ensure maintenance of body
weight at 85% of original weight. Water was available ad libitum throughout the
experiment.
There was a criteria established in the SOP to drop any mouse that does not acquire the
ability to perform on the touchscreen systems during training. Data from mice that did
not survive or were dropped due to lack of performance was not included in the final
figures.
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Figure 1
Figure 1. Male and female wild-type weight according to age. Behavioural testing
commenced when the mice were 12 weeks of age. Based on these weight curves it was
determined the 85% baseline body weight for males was 23.0g and females 20.0g, in
order to ensure motivation. (Data are mean ± SEM).
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2.4 Touchscreen Apparatus
Behavioural testing was conducted in the automated Bussey-Saksida Touchscreen
System model 81426 (Campden Instruments) for mice (Figure 2). The apparatus
consisted of a testing chamber housed within a sound and light-attenuating box (40 by 34
by 42 cm). The inner operant chamber consisted of a stainless steel grid floor, black
plastic walls, and a clear plastic cover for the top. The operant chambers were fitted with
a fan for ventilation and masking of extraneous noise and a reward tray that dispenses
liquid reward through a pump. At the other end of the chamber, opposite to the reward
tray, was a LCD monitor equipped with an infrared touchscreen controlled system by
ABET II Touch software v.3.1 (Lafayette Instruments). A black plastic cover with 5
small response windows (2cm by 2cm) was placed in front of the monitor in order to
reduce unintended responses by the tail or other body parts of the mouse (Figure 2). The
operant chambers were also equipped with a house light and a tone generator. All 5CSRTT schedules were designed and data were collected using the ABET II software.

2.5 Shaping
Mice were trained to operate the touchscreens by a series of shaping procedures (Figure
3) (Mar et al., 2013). All schedules used during the training for the 5-CSRTT were preinstalled by the ABET II software. Please refer to the appendix attached for a more
detailed operating procedure for the 5-CSRTT. For the first four days, animals were
habituated to the testing chambers using the Habituation schedules. On the first day
(Habituation 1), the mice remained in the testing chambers for 10 minutes, the house
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lights were off, and there were no touchscreen stimuli or strawberry milkshake reward
presented. For the next

Figure 2: Photograph of the touchscreen chambers. On one side of the chamber
is the touchscreen monitor covered by a black plastic mask with 5 small windows
(2 cm by 2 cm). On the opposite side of the chamber is the reward tray where
strawberry milkshake is dispensed. The entire operant chamber is enclosed within
a sound and light-attenuating box.

29

Figure 3
Figure 3: Flow chart of the 5-CSRTT schedules. On the left, all schedules pertaining to
the training phase of the touchscreen systems. On the right, training in the 5-CSRTT itself
with the 4 seconds, 2 seconds, and probe trial schedules last. Each schedule also includes
the criteria required to pass on to the next.
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two days (Habituation 2a), the mice were placed into the testing chambers for 20 minutes.
During this phase, the reward tray light was turned on and primed with strawberry
milkshake (150µl) along with a tone. The light remained on until the mouse entered the
reward tray and turned back on 10 seconds after the mouse left the tray where more
milkshake was provided (7µl) along with a tone. During the last day of habituation
(Habituation 2b), the mice were placed in the testing chambers for 40 minutes and were
subjected to the same schedule as the previous two days. Again, in this phase the mice
further strengthened the association of the reward tray light and tone with a small
milkshake reward (7µl).
Following the habituation, the mice were subjected to the initial touch schedule (one day,
30 trials). A single stimulus (a white square box, 2 cm × 2 cm) was randomly displayed
in 1 of the 5 response windows. After 30 seconds, the stimulus disappeared, the
illumination of the reward tray light coinciding with a tone, and the delivery of
strawberry milkshake reward (7µl). Once the mouse collected the milkshake, the reward
tray light extinguished and the next trial commenced after a 5 seconds inter-trial interval
(ITI; houselight off, reward tray inactive, no stimulus presented). A response to the
stimulus on the screen was rewarded with the delivery of a tone and three times the
amount of strawberry milkshake (21µl). Training continued on the initial touch schedule
until the mice completed 30 trials within 60 minutes.
During the next schedule, called must touch, the stimulus remained on the screen until the
mouse touched the correct response window, which resulted in reward of strawberry
milkshake (7µl), illumination of the tray light, and a tone. The collection of the milkshake
triggered the 5 seconds ITI after which the next trial commenced, and a new stimulus was
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presented in 1 of the 5 response windows. Each animal continued training until it
completed 30 trials within 60 minutes.
The next stage of shaping introduced the animals to the initiation procedure, a schedule
called must initiate. At the beginning of each trial, the reward tray was illuminated, and
the animal was required to initiate the stimulus delivery by a nose poke into the reward
tray. Successful initiation was indicated by the extinction of the tray light and the
subsequent display of a stimulus. After touching the stimulus and collecting the reward,
the mouse was subjected to the 5 seconds ITI before the illumination of the reward tray
light indicated the beginning of the next trial. Once animals readily initiated trials and
completed 30 trials within 60 min they moved onto the last shaping phase.
During the last shaping stage, the mouse learns to both initiate and touch the touchscreen
stimulus in its correct location. This schedule is similar to the previous must initiate
schedule, however, if a mouse touches an incorrect (non-illuminated) location on the
screen, the house lights will be turned on for 5 seconds and no reward is given. This is
followed by the regular 5 seconds ITI period prior to the start of the next trial. The mice
continue to do this phase of shaping until they are able to obtain at least 23 out of 30
trials correct within 60 minutes, on two consecutive days. Once the mice passed the
punish incorrect schedule, they went on to train in the 5-CSRTT itself.

2.6 5-CSRTT Training
Mice were trained to respond to brief flashes of light pseudo randomly displayed in one
of the five response windows on the touchscreen. Mice were tested 5 days a week, 50
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trials or 60 minutes a day. Each trial began with the illumination of the reward tray that
elicited a nose poke from the mice. The stimulus was then displayed in one of the
response windows pseudo randomly after a 5 to 10 seconds variable delay instead of an
immediate presentation of the stimulus as in the previous shaping schedules. If a mouse
prematurely touched the screen during this delay, the response was recorded as premature
and the mouse was punished with a 5 seconds time out (houselight on, reward tray
inactive). This was followed by a 5 second ITI (houselight off, reward tray inactive), after
which the illumination of the reward tray light signaled the onset of the next trial (Mar et
al., 2013). The touchscreen stimulus duration was initially set to 4 seconds, followed by a
limited holding period of 5 seconds, during which the animal was still able to respond to
the location where the stimulus appeared. Responses during stimulus presence or the
limited holding period were recorded either as correct (stimulus window) or incorrect
(any other window). A correct choice was rewarded with a tone and the illumination of
the tray light, and strawberry milkshake delivery (7µl). Reward collection turned the
reward tray light off and triggered the 5 seconds ITI. An incorrect response was punished
with a 5 seconds time out (houselight on, reward tray inactive), followed by a 5 seconds
ITI (Mar et al., 2013). Failure to respond to any window by the end of the limited holding
period was recorded as an omission and punished with a 5 seconds time out, followed by
the 5 seconds ITI before the start of the next trial. The mice continued on the 4 seconds
stimulus duration until performance was stabilized greater than 80% accuracy, less than
20% omissions for 3 consecutive days. Once the mice had passed these criteria, the
stimulus duration was reduced to 2 seconds. After reaching the same criterion with the 2
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seconds stimuli (<80% accuracy, >20% omission, for 3 consecutive days), the mice were
tested on the four 5-CSRTT probe trial schedules (Mar et al., 2013).

2.7 5-CSRTT Probe Trials
After completing training on the 5-CSRTT 2 seconds stimulus duration, the mice were
challenged by reducing the stimulus duration to 1.5, 1.0, 0.8 and 0.6 seconds. At this
shorter stimulus duration, the mice required increased attention demand in order to
successfully complete the task. The sequence of stimulus duration was presented
randomly to each mouse in order to control for order effects. Each mouse performed 2
consecutive days at a given probe trial stimulus duration (1.5s, 1.0s, 0.8s, or 0.6s), and
was then moved back onto a 2 seconds stimulus duration for 2 days before they were
subjected to the next probe. The mice continued on the probe trials until they had
completed all four, taking a total of 14 days.

2.8 Longitudinal Testing
Mice were tested as they aged at three separate time points. The first probe trials were
completed when the mice were 4-5 months of age. After the completion of the first set of
probe trials, all mice were kept on a maintenance schedule (2 seconds stimulus duration)
at least once a week until the commencement of the second set of probe trials that started
at 7 months of age. This was to ensure that the mice did not lose the ability to use the
touchscreen systems and hence would not require retraining prior to the subsequent 7 and
10-month probe trials. Upon the completion the second set of probe trials, the mice were
put back on a weekly 2 seconds maintenance schedule until the commencement of the
third set probe trials at 10 months of age.
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2.9 Touchscreen Parameters
The ABET II software automatically collected the following parameters throughout the
training and probe trial schedules in order to assess 5-CSRTT performance:
•

Accuracy: number of correct responses divided by the sum of correct and
incorrect responses (# correct /(# correct + # incorrect) × 100). Accuracy is the
main measure of sustained attention in this task.

•

Omission: number of omissions divided by total number of trials.

•

Premature Responses: total number of responses during the 5 seconds ITI divided
by the total number of trials. Premature responses reflect impulsivity in this task.

•

Perseverative Correct: total number of nose pokes in the reward tray after a
correct response, but before collection of the reward, divided by the total number
of trials. This is a measure of compulsivity/cognitive inflexibility in this task.

•

Correct Response Latency: average time it takes for the mouse to touch the screen
after the onset of the stimulus. The correct response latency reflects cognitive
processing speed in this task.

•

Reward Collection Latency: average time taken after a correct response to the
collection of the milkshake reward from the reward tray.

Statistical Analysis: All stats were performed using Graphpad Prism 6.0 software.
Comparisons between experimental groups were made by either a Student’s t-test or twoway ANOVA with repeated measures. For that, the data passed normal distribution tested
by the software. When appropriate a Tukey’s post hoc comparison test was used. In all
comparisons, p < 0.05 was considered statistically significant and all data are expressed
as mean ± SEM.
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3

Results

3.1 Training of 3xTG and 5xFAD mice in the 5-CSRTT
The performance of both the 3xTG and 5xFAD males and females did not differ from
that of control mice for touchscreen operation training (pre-training phases). The number
of trials (days) required to reach criteria across all pre-training phases did not differ
between genotypes. Similarly, when mice were trained to respond to flashes of light
displayed in one of the five spatial locations on the touchscreens (training phase),
performance of 3xTG males did not differ from that of controls in reaching criteria during
the 5-CSRTT training schedules of 4 seconds and 2 seconds (Figure 4A; 4 seconds: t(22)
= 0.7002, p = 0.4912; 2 seconds: t(18) = 1.456, p = 0.1625). Interestingly, 3xTG female
mice showed a significantly worse performance compared to controls during the 2
seconds schedule, needing more sessions to reach criteria, but were not different during
the 4 seconds schedule (Figure 4B; 4 seconds: t(19) = 0.3997, p = 0.6938; 2 seconds: t(19)
= 0.2.121, p = 0.0473). In contrast, performance of both males and females 5xFAD mice
did not differ from that of controls during the 4 seconds and 2 seconds training schedules
(Figure 4C; 4 seconds: t(22) = 0.3347, p = 0.7410; 2 seconds: t(22) = 0.0325, p = 0.9744;
Figure 4D; 4 seconds: t(21) = 0.6643, p = 0.5137; 2 seconds: t(21) = 0.9467, p = 0.3546).

3.2 Attention Capacity of 3xTG Male Mice
We investigated the performance in the 5-CSRTT for 3xTG mice longitudinally to fully
capture age-dependent deficits that are triggered by AD-like pathology. Based on
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pathology accumulation and previous behavioural experiments (Romberg et al., 2011),
we chose 4.5, 7 and 10 months to study 3xTG AD-mice.
Male 3xTG demonstrated deficits in accuracy, the main measure of attention in the 5CSRTT, compared to age-matched control mice with an overall genotype difference in
accuracy at 4.5 months (Figure 5A; RM-ANOVA, main effect of genotype, F(1,17) =
9.842, p = 0.0060; main effect of stimulus duration, F(3,51) = 25.55, p < 0.0001; no
interaction effect, F(3,51) = 0.8163, p = 0.4908). Compared to age-matched controls, 4.5
month old male 3xTG mice did not show a difference in omissions when compared to
controls (Figure 5B; RM-ANOVA, no effect of genotype, F(1,17) = 0.0018, p = 0.9663;
main effect of stimulus duration, F(3,51) = 22.88, p < 0.0001; no interaction effect, F(3,51) =
0.4374, p = 0.7272). However, transgenic mice presented a difference in correct response
latency, a measure of cognitive processing speed, when compared to controls (Figure
5C; RM-ANOVA, main effect of genotype, F(1,17) = 11.10, p = 0.0040; main effect of
stimulus duration, F(3,51) = 2.804, p = 0.049; no interaction effect, F(3,51) = 0.4679, p =
0.7059). There is no difference between genotypes for premature responses (Figure 5D;
RM-ANOVA, no effect of genotype, F(1,17) = 2.228, p = 0.1538; no effect of stimulus
duration, F(3,51) = 1.354, p = 0.2673; no interaction effect, F(3,51) = 0.3297, p = 0.78039),
number of perseverative correct responses (Figure 5E; RM-ANOVA, no effect of
genotype, F(1,17) = 0.0828, p = 0.7770; main effect of stimulus duration, F(3,51) = 3.506, p
= 0.0218; no interaction effect, F(3,51) = 1.883, p = 0.1441), or reward collection latency
(Figure 5F; RM-ANOVA, no effect of genotype, F(1,17) = 1.351, p = 0.2621; no effect of
stimulus duration, F(3,51) = 0.7123, p = 0.5492; no interaction effect, F(3,51) = 1.165, p =
0.3321).
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Figure 5: Performance and response measures of 4.5 month-old 3xTG Males
tested at University of Western Ontario during the 5-CSRTT probe trials. Mice
were subject to a series of probe trial schedules and the average values of the sessions
are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency.
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward
collection latency (3xTG males n=11, WT males n=8, data are mean ± SEM,
**p<0.01)
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At 7 months, male 3xTG mice showed a difference in accuracy compared to age-matched
control littermates (Figure 6A; RM-ANOVA, no effect of genotype, F(1,17) = 4.385, p =
0.0516; main effect of stimulus duration, F(3,51) = 26.74, p < 0.0001; main interaction
effect, F(3,51) = 3.092, p = 0.0351) and post-hoc analysis revealed that they had a
significantly lower accuracy at the 0.6s stimulus duration during the probe trials (Fig.
6A). Similarly to the 4.5 month-old transgenic mice, there were no differences between
3xTG and controls in omissions (Figure 6B; RM-ANOVA, no effect of genotype, F(1,17)
= 0.5091, p = 0.4852; main effect of stimulus duration, F(3,51) = 26.35, p < 0.0001; no
interaction effect, F(3,51) = 0.1061, p = 0.9562). The 7 month old transgenic males also
had significantly higher correct response latencies when compared to age-matched
controls (Figure 6C; RM-ANOVA, main effect of genotype, F(1,17) = 9.434, p = 0.0069;
main effect of stimulus duration, F(3,51) = 4.252, p = 0.0093; no interaction effect, F(3,51) =
0.5739, p = 0.6348). There was no difference between genotypes in premature responses
(Figure 6D; RM-ANOVA, no effect of genotype, F(1,17) = 2.076, p = 0.1677; main effect
of stimulus duration, F(3,51) = 3.532, p = 0.0211; no interaction effect, F(3,51) = 0.2442, p =
0.8651), perseverative correct responses (Figure 6E; RM-ANOVA, no effect of
genotype, F(1,17) = 0.4685, p = 0.5029; main effect of stimulus duration, F(3,51) = 4.866, p
= 0.0047; no interaction effect, F(3,51) = 0.7868, p = 0.5068), or reward collection latency
(Figure 6F; RM-ANOVA, no effect of genotype, F(1,17) = 0.9133, p = 0.3526; no effect of
stimulus duration, F(3,51) = 1.391, p = 0.2561; main interaction effect, F(3,51) = 2.117, p =
0.1095).
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Figure 6. Performance and response measures of 7 month-old 3xTG Males at the
University of Western Ontario during the 5-CSRTT probe trials. Mice were
subject to a series of probe trial schedules and the average values of the sessions are
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D,
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG males n=11, WT males n=8, data are mean ± SEM, **p<0.01)
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Ten month old 3xTG males showed both a genotype and interaction difference in
accuracy compared to age-matched controls (Figure 7A; RM-ANOVA, main effect of
genotype, F(1,13) = 5.261, p = 0.0391; main effect of stimulus duration, F(3,39) = 19.81, p <
0.0001; main interaction effect, F(3,39) = 4.661, p = 0.0071). Post-hoc analysis revealed
that they had significantly lower accuracy at the 0.6s stimulus duration during the probe
trials (Fig. 7A). Moreover, the 10 months old 3xTG males also presented a difference in
omissions during the task when compared to controls (Figure 7B; RM-ANOVA, main
effect of genotype, F(1,13) = 9.371, p = 0.0091; main effect of stimulus duration, F(3,39) =
16.91, p < 0.0001; no interaction effect, F(3,39) = 2.4111, p = 0.0815). Male 3xTG mice
also had a significant difference in correct response latency at this age (Figure 7C; RMANOVA, main effect of genotype, F(1,13) = 4.709, p = 0.0491; no effect of stimulus
duration, F(3,39) = 0.5234, p = 0.6687; no interaction effect, F(3,39) = 0.3645, p = 0.7790).
In contrast, the 10 month old 3xTG mice did not reveal a difference in premature
responses between the two genotypes (Figure 7D; RM-ANOVA, no effect of genotype,
F(1,13) = 0.1053, p = 0.7507; no effect of stimulus duration, F(3,39) = 1.057, p = 0.3782; no
interaction effect, F(3,39) = 1.760, p = 0.1708). Perseverative correct, which reflects
compulsivity, was different between genotypes (Figure 7E; RM-ANOVA, main effect of
genotype, F(1,13) = 5.649, p = 0.0335; no effect of stimulus duration, F(3,39) = 1.676, p =
0.1880; no interaction effect, F(3,39) = 0.4492, p = 0.7193). Lastly, reward collection
latency was not different between genotypes (Figure 7F; RM-ANOVA, no effect of
genotype, F(1,13) = 0.9227, p = 0.3543; no effect of stimulus duration, F(3,39) = 1.678, p =
0.1876; no interaction effect, F(3,39) = 1.621, p = 0.2000).
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Figure 7. Performance and response measures of 10 month-old 3xTG Males at
the University of Western Ontario during the 5-CSRTT probe trials. Mice were
subject to a series of probe trial schedules and the average values of the sessions are
plotted. Mice were subject to a series of probe trials and the average values of the
sessions are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response
latency. D, Mean premature responses. E, Mean perseverative correct. F, Mean reward
collection latency (3xTG males n=8, WT males n=7, data are mean ± SEM, *p<0.05
and **p<0.01)
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3.3 Attention Capacity in 3xTG Female Mice
We also investigated the performance of female 3xTG mice longitudinally in the 5CSRTT. Similar to males, female 3xTG mice also revealed differences in both accuracy
and correct response latencies throughout all three probe trials.
The 4.5 month old 3xTG females showed decreased accuracy compared to controls
(Figure 8A; RM-ANOVA, main effect of genotype, F(1,18) = 4.523, p = 0.0475; main
effect of stimulus duration, F(3,54) = 18.79, p < 0.0001; no interaction effect, F(3,54) =
1.593, p = 0.2017) and increased omissions (Figure 8B; RM-ANOVA, no effect of
genotype, F(1,18) = 3.604, p = 0.0738; main effect of stimulus duration, F(3,54) = 69.94, p <
0.0001; main interaction effect, F(3,54) = 2.936, p = 0.0414). Post-hoc analysis revealed a
significant increase in omissions at the 0.6s stimulus duration (Fig. 8B). In addition, the
transgenic females showed both a genotype and interaction difference in correct response
latency (Figure 8C; RM-ANOVA, main effect of genotype, F(1,18) = 12.44, p = 0.0024;
no effect of stimulus duration, F(3,54) = 1.490, p = 0.2276; main interaction effect, F(3,54) =
3.772, p = 0.0157) with post-hoc analysis revealing a significant increase in latency at the
0.6s stimulus duration (Fig. 8C). There were no other differences between 4.5 months old
3xTG females and age-matched controls during the first probe trial in premature
responses (Figure 8D; RM-ANOVA, no effect of genotype, F(1,18) = 3.886, p = 0.0643;
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Figure 8. Performance and response measures of 4.5 month-old 3xTG Females at
the University of Western Ontario during the 5-CSRTT probe trials. Mice were
subject to a series of probe trial schedules and the average values of the sessions are
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D,
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG females n=10, WT females n=10, data are mean ± SEM, *p<0.05,
**p<0.01 and ****p<0.0001)
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no effect of stimulus duration, F(3,54) = 0.4987, p = 6848; no interaction effect, F(3,54) =
0.4138, p = 0.7437) perseverative correct (Figure 8E; RM-ANOVA, no effect of
genotype, F(1,18) = 1.127, p = 0.3025; main effect of stimulus duration, F(3,54) = 4.963, p =
0.0041; no interaction effect, F(3,54) = 1.330, p = 0.2742), or reward collection latency
(Figure 8F; RM-ANOVA, no effect of genotype, F(1,18) = 2.551, p = 0.1276; no effect of
stimulus duration, F(3,54) = 2.590, p = 0.0622; no interaction effect, F(3,54) = 0.8387, p =
0.4786).
Seven month-old 3xTG females showed a significantly lower accuracy compared to agematched controls (Figure 9A; RM-ANOVA, main effect of genotype, F(1,17) = 10.48, p =
0.0048; main effect of stimulus duration, F(3,51) = 27.11, p < 0.0001; no interaction effect,
F(3,51) = 1.860, p = 0.1481). In addition, they also had higher omissions (Figure 9B; RMANOVA, main effect of genotype, F(1,17) = 4.890, p = 0.0410; main effect of stimulus
duration, F(3,51) = 19.63, p < 0.0001; no interaction effect, F(3,51) = 0.9319, p = 0.14321)
and correct response latencies (Figure 9C; RM-ANOVA, main effect of genotype, F(1,17)
= 10.35, p = 0.0051; no effect of stimulus duration, F(3,51) = 0.4251, p = 0.7358; no
interaction effect, F(3,51) = 0.3717, p = 0.7737). There were no differences between the
genotypes in premature responses (Figure 9D; RM-ANOVA, no effect of genotype,
F(1,17) = 0.3622, p = 0.5552; main effect of stimulus duration, F(3,51) = 2.890, p = 0.0433;
no interaction effect, F(3,51) = 0.7168, p = 0.5466), perseverative correct responses
(Figure 9E; RM-ANOVA, no effect of genotype, F(1,17) = 6.392, p = 0.0517; main effect
of stimulus duration, F(3,51) = 4.773, p = 0.0052; no interaction effect, F(3,51) = 0.0653, p =
0.978) or reward collection latencies (Figure 9F; RM-ANOVA, no effect of genotype,
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Figure 9. Performance and response measures of 7 month-old 3xTG Females at
the University of Western Ontario during the 5-CSRTT probe trials. Mice were
subject to a series of probe trial schedules and the average values of the sessions are
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D,
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG females n=10, WT females n=9, data are mean ± SEM, *p<0.05 and
**p<0.01)
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F(1,17) = 0.0068, p = 0.9353; no effect of stimulus duration, F(3,51) = 1.579, p = 0.2058; no
interaction effect, F(3,51) = 1.118, p = 0.3506).
Surprisingly, 10 month-old 3xTG females did not show a significant difference in
accuracy when compared to controls (Figure 10A; RM-ANOVA, no effect of genotype,
F(1,16) = 2.992, p = 0.1029; main effect of stimulus duration, F(3,48) = 38.54, p < 0.0001;
no interaction effect, F(3,48) = 0.7550, p = 0.5249), or omissions (Figure 10B; RMANOVA, no effect of genotype, F(1,16) = 3.080, p = 0.0984; main effect of stimulus
duration, F(3,48) = 29.15, p < 0.0001; no interaction effect, F(3,48) = 1.189, p = 0.3237).
The 3xTG females did show a higher correct response latency compared to controls
(Figure 10C; RM-ANOVA, main effect of genotype, F(1,16) = 13.95, p = 0.0018; no effect
of stimulus duration, F(3,48) = 0.8806, p = 0.4578; no interaction effect, F(3,48) = 1.028, p =
0.3885). However, no differences were observed between the 10 month-old genotypes in
premature responses (Figure 10D; RM-ANOVA, no effect of genotype, F(1,16) = 0.8635,
p = 0.3666; main effect of stimulus duration, F(3,48) = 3.301, p = 0.0280; no interaction
effect, F(3,48) = 0.5091, p = 0.6779), perseverative correct (Figure 10E; RM-ANOVA, no
effect of genotype, F(1,16) = 3.542, p = 0.0817; main effect of stimulus duration, F(3,48) =
4.275, p = 0.0094; no interaction effect, F(3,48) = 1293, p = 0.2876), or reward collection
latency (Figure 10F; RM-ANOVA, no effect of genotype, F(1,16) = 0.0590, p = 0.8111;
main effect of stimulus duration, F(3,48) = 1.208, p = 0.3170; no interaction effect, F(3,48) =
1.118, p = 0.3510).
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Figure 10. Performance and response measures of 10 month-old 3xTG Females at
the University of Western Ontario during the 5-CSRTT probe trials. Mice were
subject to a series of probe trial schedules and the average values of the sessions are
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D,
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG females n=9, WT females n=9, data are mean ± SEM, **p<0.01)
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3.4 Reproducibility of 3xTG Data Between Different Sites
In order to test for reproducibility of data using the 5-CSRTT, age-matched 3xTG mice
and controls were run at two separate sites, at the University of Western Ontario (site 1)
and at the University of Guelph (site 2). Due to the potential for the greatest agedependent deficits related to AD-pathology, the accuracy data for the 10 month-old mice
was analyzed to determine whether data obtained with touchscreens are indeed
reproducible. For that we obtained data from Dr. Boyer Winters’ laboratory (Data
obtained by the PhD student Daniel Palmer) who collaborates in this project. It should be
noted that the results we obtained with 3xTG male mice in site 1 were already
reproducing data previously published for these mice in touchscreens (Romberg et al
2011). No difference was observed in performance of 10 month-old wild-type males
between sites (Figure 11A; RM-ANOVA, no effect of genotype, F(1,15) = 1.153, p =
0.2999; main effect of stimulus duration, F(3,45) = 13.86, p < 0.0001; no interaction effect,
F(3,45) = 0.3881, p = 0.7621) and no difference was observed in performance of 10 monthold 3xTG males between sites (Figure 11B; RM-ANOVA, no effect of genotype, F(1,14) =
2.362, p = 0.1466; main effect of stimulus duration, F(3,42) = 28.68, p < 0.0001; no
interaction effect, F(3,42) = 1.681, p = 0.1856). Similarly, we observed no difference
between sites in performance of female wild-type mice (Figure 11C; RM-ANOVA, no
effect of genotype, F(1,14) = 0.9362, p = 0.3497; main effect of stimulus duration, F(3,42) =
21.76, p < 0.0001; no interaction effect, F(3,42) = 0.2185, p = 0.8830), or the female 3xTG
mice (Figure 11D; RM-ANOVA, no effect of genotype, F(1,17) = 1.614, p = 0.2210; main
effect of stimulus duration, F(3,51) = 41.20, p < 0.0001; no interaction effect, F(3,51) =
0.3616, p = 0.7810). Despite some minor differences when we compared other
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Figure 11. Comparison of the performance and response measures of 10 monthold 3xTG and Wild-type Males and Females tested at the University of Western
Ontario (London) and at the University of Guelph (Guelph) during the 5-CSRTT
probe trials. Mice were subject to a series of probe trial schedules and the average
values of the sessions are plotted. A, Mean accuracy for WT males. B, Mean accuracy
for 3xTG males from both sites. C, Mean accuracy for WT females. D, Mean accuracy
for 3xTG females. (Data are mean ± SEM).
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parameters in all the ages, the results were mostly reproducible between sites (data not
shown). Since there were no differences within groups of control and 3xTG mice, we
analysed data between the two sites for all ages in order to increase statistical power and
define robust age-dependent AD-related phenotypes in the 5-CSRTT touchscreen tests
for this mouse line.
Our analysis reveals that 3xTG male mice presented attention deficits when data were
combined with decreased accuracy of 4.5 month-old mice (Figure 12A; RM-ANOVA,
main effect of genotype, F(1,38) = 5.176, p = 0.0286; main effect of stimulus duration,
F(3,114) = 59.45, p < 0.0001; no interaction effect, F(3,114) = 0.8496, p = 0.4696), however
we did not observe a difference in omissions (Figure 12B; RM-ANOVA, no effect of
genotype, F(1,38) = 0.2818, p = 0.5986; main effect of stimulus duration, F(3,114) = 61.76, p
< 0.0001; no interaction effect, F(3,114) = 0.3983, p = 0.7545). The combined data also
demonstrated a difference in correct response latency between genotypes (Figure 12C;
RM-ANOVA, main effect of genotype, F(1,38) = 13.44, p = 0.0008; main effect of
stimulus duration, F(3,114) = 10.70, p < 0.0001; no interaction effect, F(3,114) = 0.4505, p =
0.7174). No differences were observed between the combined 4.5 month-old 3xTG males
and controls in premature responses (Figure 12D; RM-ANOVA, no effect of genotype,
F(1,38) = 0.1597, p = 0.6917; main effect of stimulus duration, F(3,114) = 3.496, p = 0.0186;
no interaction effect, F(3,114) = 0.0727, p = 0.9745), perseverative correct (Figure 12E;
RM-ANOVA, no effect of genotype, F(1,38) = 1.989, p = 0.1666; main effect of stimulus
duration, F(3,114) = 9.698, p < 0.0001; no interaction effect, F(3,114) = 1.845, p = 0.1430),
or reward collection latency (Figure 12F; RM-ANOVA, no effect of genotype, F(1,38) =
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Figure 12. Performance and response measures of the combined data for 4.5
month-old 3xTG Males at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG males n=22, WT males n=19, data are mean ± SEM, *p<0.05 and
***p<0.001)
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1.899, p = 0.1762; no effect of stimulus duration, F(3,114) = 1.049, p = 0.3740; no
interaction effect, F(3,114) = 0.3240, p = 0.8080).
Combined data obtained with 7 month-old 3xTG and control male mice showed both a
genotype and interaction difference in accuracy (Figure 13A; RM-ANOVA, main effect
of genotype, F(1,31) = 7.876, p = 0.0086; main effect of stimulus duration, F(3,93) = 48.29, p
< 0.0001; main interaction effect, F(3,93) = 3.546, p = 0.0175) and a Post-hoc analysis
revealed a significant difference between at the 0.6s stimulus duration (Fig. 13A). There
were no differences observed for omissions (Figure 13B; RM-ANOVA, no effect of
genotype, F(1,31) = 0.9227, p = 0.3442; main effect of stimulus duration, F(3,93) = 59.83, p
< 0.0001; no interaction effect, F(3,93) = 0.0046, p = 0.9996). The combined data
demonstrated that 7 month-old 3xTG males continued to have higher correct response
latencies compared to age-matched controls (Figure 13C; RM-ANOVA, main effect of
genotype, F(1,31) = 14.80, p = 0.0006; main effect of stimulus duration, F(3,93) = 10.44, p <
0.0001; no interaction effect, F(3,93) = 1.077, p = 0.3692). No difference in performance
was observed in premature responses (Figure 13D; RM-ANOVA, no effect of genotype,
F(1,31) = 4802, p = 0.4935; main effect of stimulus duration, F(3,93) = 3.449, p = 0.0198; no
interaction effect, F(3,93) = 0.6072, p = 0.6120), number of perseverative correct responses
(Figure 13E; RM-ANOVA, no effect of genotype, F(1,31) = 0.0082, p = 0.9285; main
effect of stimulus duration, F(3,93) = 5.594, p = 0014; no interaction effect, F(3,93) =
0.8452, p = 0.4726), or reward collection latency (Figure 13F; RM-ANOVA, no effect
of genotype, F(1,31) = 0.2646, p = 0.6107; no effect of stimulus duration, F(3,93) = 1.553, p
= 0.2060; no interaction effect, F(3,93) = 1.904, p = 0.0889).
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Figure 13. Performance and response measures of the combined data for 7
month-old 3xTG Males at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG males n=18, WT males n=15, data are mean ± SEM, **p<0.01 and
***p<0.001)
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At 10 months of age, the combined data demonstrated that male 3xTG mice continued to
display both a genotype and interaction difference in accuracy (Figure 14A; RMANOVA, main effect of genotype, F(1,31) = 5.459, p = 0.0261; main effect of stimulus
duration, F(3,93) = 43.61, p < 0.0001; main interaction effect, F(3,93) = 5.000, p = 0.0029).
A post-hoc analysis revealed a difference between genotypes at the 0.6s stimulus duration
(Fig. 14A). The data from both sites also revealed a difference in omissions when we
compared the male mice from the two genotypes (Figure 14B; RM-ANOVA, main effect
of genotype, F(1,31) = 4.610, p = 0.0397; main effect of stimulus duration, F(3,93) = 43.38, p
< 0.0001; no interaction effect, F(3,93) = 1.794, p = 0.1538). Likewise, the transgenic
males continued to demonstrate increased correct response latency compared to controls
(Figure 14C; RM-ANOVA, main effect of genotype, F(1,31) = 7.398, p = 0.0106; no effect
of stimulus duration, F(3,93) = 0.4928, p = 0.6882; no interaction effect, F(3,93) = 0.6931, p
= 0.5585). However, no differences in premature responses (Figure 14D; RM-ANOVA,
no effect of genotype, F(1,31) = 0.0664, p = 0.7983; no effect of stimulus duration, F(3,93) =
1.613, p = 0.1917; no interaction effect, F(3,93) = 0.2399, p = 0.8683), perseverative
correct (Figure 14E; RM-ANOVA, no effect of genotype, F(1,31) = 0.3807, p = 0.5417;
main effect of stimulus duration, F(3,93) = 3.643, p = 0.0194; no interaction effect, F(3,93) =
.4961, p = 0.6859) or reward collection latency (Figure 14F; RM-ANOVA, no effect of
genotype, F(1,31) = 0.2939, p = 0.5916; no effect of stimulus duration, F(3,93) = 2.573, p =
0.0587; no interaction effect, F(3,93) = 0.4875, p = 0.6918) were observed in the data from
both sites.
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Figure 14. Performance and response measures of the combined data for 10
month-old 3xTG Males at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG males n=16, WT males n=17, data are mean ± SEM, *p<0.05 and
***p<0.001)
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The combination of data between sites also revealed the 3xTG females to have a
significantly lower accuracy during the 4.5 month-old probes (Figure 15A; RMANOVA, main effect of genotype, F(1,35) = 6.358, p = 0.0164; main effect of stimulus
duration, F(3,105) = 48.35, p < 0.0001; no interaction effect, F(3,105) = 0.8023, p = 0.4953),
but no difference in omissions (Figure 15B; RM-ANOVA, no effect of genotype, F(1,35) =
1.623, p = 0.2111; main effect of stimulus duration, F(3,105) = 94.38, p < 0.0001; no
interaction effect, F(3,105) = 0.9048, p = 0.4415). In addition, female 3xTG mice showed
an increase in correct response latency (Figure 15C; RM-ANOVA, main effect of
genotype, F(1,35) = 16.26, p = 0.0003; main effect of stimulus duration, F(3,105) = 3.911, p
= 0.0108; no interaction effect, F(3,105) = 1.111, p = 0.3480), and decreased premature
responses (Figure 15D; RM-ANOVA, main effect of genotype, F(1,35) = 5.465, p =
0.0252; no effect of stimulus duration, F(3,105) = 0.8707, p = 0.4588; no interaction effect,
F(3,105) = 0.1364, p = 0.9381). The combined data for the 4.5 month-old 3xTG females
and controls did not reveal a difference in perseverative correct responses (Figure 15E;
RM-ANOVA, no effect of genotype, F(1,35) = 1.563, p = 0.2195; main effect of stimulus
duration, F(3,105) = 8.066, p < 0.0001; no interaction effect, F(3,105) = 0.6851, p = 0.5631),
or reward collection latency (Figure 15F; RM-ANOVA, no effect of genotype, F(1,35) =
0.1229, p = 0.7280; no effect of stimulus duration, F(3,105) = 1.947, p = 0.1266; no
interaction effect, F(3,105) = 0.8414, p = 0.4742).
Combined data between sites for probe trials at 7 months of age showed 3xTG females to
have deficits in accuracy compared to controls (Figure 16A; RM-ANOVA, main effect
of genotype, F(1,32) = 6.825, p = 0.0136; main effect of stimulus duration, F(3,96) = 52.40, p
< 0.0001; no interaction effect, F(3,96) = 0.8580, p = 0.4657). Interestingly, the combined
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Figure 15. Performance and response measures of the combined data for 4.5
month-old 3xTG Females at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG females n=20, WT females n=17, data are mean ± SEM, *p<0.05 and
***p<0.001)
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Figure 16. Performance and response measures of the combined data for 7
month-old 3xTG Females at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG females n=20, WT females n=15, data are mean ± SEM, *p<0.05 and
**p<0.01)
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data revealed that the 3xTG females had deficits in omissions compared to controls
(Figure 16B; RM-ANOVA, main effect of genotype, F(1,32) = 4.552, p = 0.0406; main
effect of stimulus duration, F(3,96) = 43.13, p < 0.0001; no interaction effect, F(3,96) =
1.413, p = 0.2437). Differences were also observed between genotypes in correct
response latency (Figure 16C; RM-ANOVA, main effect of genotype, F(1,32) = 10.87, p =
0.0024; main effect of stimulus duration, F(3,96) = 2.868, p = 0.0405; no interaction effect,
F(3,96) = 0.1061, p = 0.9563). The combined data revealed no differences between females
3xTG and control mice in premature responses (Figure 16D; RM-ANOVA, no effect of
genotype, F(1,32) = 0.0202, p = 0.8880; main effect of stimulus duration, F(3,96) = 4.567, p
= 0.0049; no interaction effect, F(3,96) = 0.3085, p = 0.8192), perseverative correct
(Figure 16E; RM-ANOVA, no effect of genotype, F(1,32) = 4.868, p = 0.0547; main effect
of stimulus duration, F(3,96) = 7.045, p = 0.0002; no interaction effect, F(3,96) = 0.0609, p =
0.9802), or reward collection latency (Figure 16F; RM-ANOVA, no effect of genotype,
F(1,32) = 0.3668, p = 0.5490; no effect of stimulus duration, F(3,96) = 2.188, p = 0.0945; no
interaction effect, F(3,96) = 1.831, p = 0.1467).
At 10 months of age, combined data revealed female 3xTG mice to have significantly
decreased accuracy compared to controls (Figure 17A; RM-ANOVA, main effect of
genotype, F(1,33) = 5.324, p = 0.0275; main effect of stimulus duration, F(3,99) = 63.86, p <
0.0001; no interaction effect, F(3,99) = 1.069, p = 0.3659). However, no difference was
observed in omissions (Figure 17B; RM-ANOVA, no effect of genotype, F(1,33) = 0.0313,
p = 0.8606; main effect of stimulus duration, F(3,99) = 52.14, p < 0.0001; no interaction
effect, F(3,99) = 1.039, p = 0.3788). The combined data also demonstrated that transgenic
females have an increased correct response latency compared to age-matched controls
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(Figure 17C; RM-ANOVA, main effect of genotype, F(1,33) = 9.202, p = 0.0047; main
effect of stimulus duration, F(3,99) = 4.156, p = 0.0081; no interaction effect, F(3,99) =
0.9700, p = 0.4101). The 10 month-old females did not display any differences in
premature responses (Figure 17D; RM-ANOVA, no effect of genotype, F(1,33) = 0.0873,
p = 0.7695; no effect of stimulus duration, F(3,99) = 1.883, p = 0.1374; no interaction
effect, F(3,99) = 0.1473, p = 0.9312), perseverative correct, although there was a tendency
for the transgenic mice to have lower responses compared to controls, (Figure 17E; RMANOVA, no effect of genotype, F(1,33) = 3.663, p = 0.0643; main effect of stimulus
duration, F(3,99) = 8.001, p < 0.0001; no interaction effect, F(3,99) = 2.262, p = 0.0860), or
reward collection latency (Figure 17F; RM-ANOVA, no effect of genotype, F(1,33) =
1.385, p = 0.2477; no effect of stimulus duration, F(3,99) = 0.4324, p = 0.7303; no
interaction effect, F(3,99) = 1.078, p = 0.3621).
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Figure 17. Performance and response measures of the combined data for 10
month-old 3xTG Females at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (3xTG females n=19, WT females n=16, data are mean ± SEM, *p<0.05 and
**p<0.01)
63

3.5 Attention Capacity of Male 5xFAD mice
Several AD mouse lines have been generated presenting distinct deficits at different ages
(Webster et al., 2014). Whether distinct AD mice may present similar phenotypes that
could be predictable for future interventions needs to be clarified. We therefore obtained
data for attentional performance in a second AD mouse line which presents fast
developing amyloidosis due to combined mutations in APP and PSEN1, the 5xFAD line
(Oakley et al., 2006). We chose to test this mouse line longitudinally at 4.5, 7 and 10
months of age on the 5-CSRTT based on data from previous experiments that have
shown the progression of AD-like pathology (Oakley et al., 2006). In addition, testing at
the same ages as the 3xTG mice allowed us to determine to what extent there were any
age-dependent differences between the mouse lines.
The 4.5 month-old 5xFAD male mice did not show any difference in accuracy compared
to controls during the first probe trials (Figure 18A; RM-ANOVA, no effect of genotype,
F(1,19) = 0.2634, p = 0.6137; main effect of stimulus duration, F(3,57) = 27.06, p < 0.0001;
no interaction effect, F(3,57) = 0.8136, p = 0.4917). In addition, performance did not differ
between the 5xFAD males and controls in omissions (Figure 18B; RM-ANOVA, no
effect of genotype, F(1,19) = 0.4977, p = 0.4891; main effect of stimulus duration, F(3,57) =
54.79, p < 0.0001; no interaction effect, F(3,57) = 0.5362, p = 0.6594), correct response
latency (Figure 18C; RM-ANOVA, no effect of genotype, F(1,19) = 3.832, p = 0.0651; no
effect of stimulus duration, F(3,57) = 2.645, p = 0.0577; no interaction effect, F(3,57) =
0.1085, p = 0.9548), premature responses (Figure 18D; RM-ANOVA, no effect of
genotype, F(1,19) = 0.0606, p = 0.8082; main effect of stimulus duration, F(3,57) = 2.918, p
= 0.0481; no interaction effect, F(3,57) = 6.003, p = 0.0013), perseverative correct
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Figure 18. Performance and response measures for 4.5 month-old 5xFAD Males
at the University of Western Ontario during the 5-CSRTT probe trials. Mice
were subject to a series of probe trial schedules and the average values of the sessions
are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency.
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward
collection latency (5xFAD males n=12, WT males n=12, data are mean ± SEM)
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responses (Figure 18E; RM-ANOVA, no effect of genotype, F(1,19) = 1.749, p = 0.2017;
main effect of stimulus duration, F(3,57) = 3.097, p = 0.0339; no interaction effect, F(3,57) =
0.7475, p = 0.5283), or reward collection latency (Figure 18F; RM-ANOVA, no effect
of genotype, F(1,19) = 0.0077, p = 0.9310; no effect of stimulus duration, F(3,57) = 0.1122, p
= 0.9527; no interaction effect, F(3,57) = 0.05497, p = 0.6504).
Similarly, at 7 months, performance of 5xFAD males did not differ from that of controls
in accuracy (Figure 19A; RM-ANOVA, no effect of genotype, F(1,21) = 2.403, p =
0.1360; main effect of stimulus duration, F(3,63) = 28.34, p < 0.0001; main interaction
effect, F(3,63) = 3.157, p = 0.0308), or omissions (Figure 19B; RM-ANOVA, no effect of
genotype, F(1,21) = 0.6592, p = 0.4260; main effect of stimulus duration, F(3,63) = 29.56, p
< 0.0001; no interaction effect, F(3,63) = 1.304, p = 0.2811). Although no significant
differences were observed between genotypes in correct response latency (Figure 19C;
RM-ANOVA, no effect of genotype, F(1,21) = 4.807, p = 0.0562; no effect of stimulus
duration, F(3,63) = 1.333, p = 0.2718; no interaction effect, F(3,63) = 0.3872, p = 0.7626),
there is a strong tendency for 5xFAD males to take longer to respond. In addition, no
differences were observed between genotypes in premature responses (Figure 19D; RMANOVA, no effect of genotype, F(1,21) = 0.0034, p = 0.9544; no effect of stimulus
duration, F(3,63) = 2.260, p = 0.0901; no interaction effect, F(3,63) = 2.823, p = 0.0558), or
perseverative correct (Figure 19E; RM-ANOVA, no effect of genotype, F(1,21) = 2.492, p
= 0.1293; main effect of stimulus duration, F(3,63) = 3.090, p = 0.0333; no interaction
effect, F(3,63) = 0.9327, p = 0.4302). The male 5xFAD mice did have higher reward
collection latencies compared to controls (Figure 19F; RM-ANOVA, main effect of
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Figure 19. Performance and response measures for 7 month-old 5xFAD Males at
the University of Western Ontario during the 5-CSRTT probe trials. Mice were
subject to a series of probe trial schedules and the average values of the sessions are
plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency. D,
Mean premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (5xFAD males n=12, WT males n=11, data are mean ± SEM)
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genotype, F(1,21) = 4.671, p = 0.0424; no effect of stimulus duration, F(3,63) = 1.290, p =
0.2856; no interaction effect, F(3,63) = 0.4530, p = 0.7161).
Interestingly, at 10 months of age, 5xFAD male mice revealed decreased accuracy, the
main measure of attention in the 5-CSRTT, with both a genotype and interaction
difference (Figure 20A; RM-ANOVA, main effect of genotype, F(1,22) = 5.824, p =
0.0293; main effect of stimulus duration, F(3,66) = 54.53, p < 0.0001; main interaction
effect, F(3,66) = 2.879, p = 0.0425). Post-hoc analysis demonstrated significant differences
at both the 0.8s and 0.6s stimulus duration between genotypes (Fig. 20A). No differences
in omission were observed between transgenic and wild-type males (Figure 20B; RMANOVA, no effect of genotype, F(1,22) = 3.030, p = 0.0957; main effect of stimulus
duration, F(3,66) = 24.59, p < 0.0001; no interaction effect, F(3,66) = 1.165, p = 0.3296). In
addition, 10 month-old 5xFAD males had a significantly higher correct response latency
compared to age-matched controls (Figure 20C; RM-ANOVA, main effect of genotype,
F(1,22) = 15.38, p = 0.0007; main effect of stimulus duration, F(3,66) = 23.87, p < 0.0001;
no interaction effect, F(3,66) = 1.618, p = 0.1936), but showed no difference in premature
responses (Figure 20D; RM-ANOVA, no effect of genotype, F(1,22) = 0.4828, p = 0.4944;
main effect of stimulus duration, F(3,66) = 4.437, p = 0.0067; no interaction effect, F(3,66) =
1.282, p = 0.2879). In contrast, 5xFAD males demonstrated a difference from control
mice in both perseverative correct responses (Figure 20E; RM-ANOVA, main effect of
genotype, F(1,22) = 11.66, p = 0.0025; main effect of stimulus duration, F(3,66) = 10.18, p <
0.0001; no interaction effect, F(3,66) = 2.223, p = 0.0937), and reward collection latency
(Figure 20F; RM-ANOVA, main effect of genotype, F(1,22) = 34.34, p < 0.0001; no effect
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Figure 20. Performance and response measures for 10 month-old 5xFAD Males
at the University of Western Ontario during the 5-CSRTT probe trials. Mice
were subject to a series of probe trial schedules and the average values of the sessions
are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency.
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward
collection latency (5xFAD males n=12, WT males n=12, data are mean ± SEM,
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001)
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of stimulus duration, F(3,66) = 1.617, p = 0.1937; no interaction effect, F(3,66) = 1.954, p =
0.1294) compared to controls.

3.6 Performance of 5xFAD Female Mice
We also investigated whether 5xFAD female mice display any deficits in the 5-CSRTT
compared to controls. 4.5 month-old 5xFAD females did not show a difference in
accuracy compared to wild-type controls (Figure 21A; RM-ANOVA, no effect of
genotype, F(1,21) = 0.3098, p = 0.5837; main effect of stimulus duration, F(3,63) = 36.61, p
< 0.0001; no interaction effect, F(3,63) = 1.187, p = 0.3221). Likewise, no difference was
observed between the genotypes in omissions (Figure 21B; RM-ANOVA, no effect of
genotype, F(1,21) = 0.0742, p = 0.7880; main effect of stimulus duration, F(3,63) = 42.37, p
< 0.0001; no interaction effect, F(3,63) = 2.264, p = 0.0897), correct response latency
(Figure 21C; RM-ANOVA, no effect of genotype, F(1,21) = 0.7868, p = 0.3851; main
effect of stimulus duration, F(3,63) = 12.57, p < 0.0001; no interaction effect, F(3,63) =
0.7074, p = 0.5512), premature responses (Figure 21D; RM-ANOVA, no effect of
genotype, F(1,21) = 0.0122, p = 0.9131; main effect of stimulus duration, F(3,63) = 4.332, p
= 0.0077; no interaction effect, F(3,63) = 0.01206, p = 0.9476), perseverative correct
(Figure 21E; RM-ANOVA, no effect of genotype, F(1,21) = 2.605, p = 0.1214; main effect
of stimulus duration, F(3,63) = 3.665, p = 0.0168; no interaction effect, F(3,63) = 0.1445, p =
0.9328), or reward collection latency (Figure 21F; RM-ANOVA, no effect of genotype,
F(1,21) = 0.0005, p = 0.9819; no effect of stimulus duration, F(3,63) = 1.700, p = 0.1760; no
interaction effect, F(3,63) = 0.1528, p = 0.9275).
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Figure 21. Performance and response measures for 4.5 month-old 5xFAD
Females at the University of Western Ontario during the 5-CSRTT probe trials.
Mice were subject to a series of probe trial schedules and the average values of the
sessions are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response
latency. D, Mean premature responses. E, Mean perseverative correct. F, Mean reward
collection latency (5xFAD females n=12, WT females n=11, data are mean ± SEM)
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The 7 month-old female 5xFAD mice did not reveal a difference in accuracy, albeit there
was a tendency for worse performance by the transgenic mice (Figure 22A; RMANOVA, no effect of genotype, F(1,17) = 3.081, p = 0.0972; main effect of stimulus
duration, F(3,51) = 28.75, p < 0.0001; no interaction effect, F(3,51) = 1.407, p = 0.2513) or
omissions (Figure 22B; RM-ANOVA, no effect of genotype, F(1,17) = 1.937, p = 0.1819;
main effect of stimulus duration, F(3,51) = 20.93, p < 0.0001; no interaction effect, F(3,51) =
0.9139, p = 0.4408). However, 5xFAD females did display an increased correct response
latency compared to controls (Figure 22C; RM-ANOVA, main effect of genotype, F(1,17)
= 11.37, p = 0.0036; no effect of stimulus duration, F(3,51) = 1.248, p = 0.3021; no
interaction effect, F(3,51) = 1.788, p = 0.1611), but no difference was observed in
premature responses (Figure 22D; RM-ANOVA, no effect of genotype, F(1,17) = 0.5379,
p = 0.4733; no effect of stimulus duration, F(3,51) = 1.705, p = 0.1776; no interaction
effect, F(3,51) = 0.5160, p = 0.6732). A difference was observed between genotypes for
perseverative correct (Figure 22E; RM-ANOVA, main effect of genotype, F(1,17) = 6.266,
p = 0.0228; no effect of stimulus duration, F(3,51) = 2.183, p = 0.1014; no interaction
effect, F(3,51) = 0.5370, p = 0.6590), as well as reward collection latency (Figure 22F;
RM-ANOVA, main effect of genotype, F(1,17) = 5.645, p = 0.0295; main effect of
stimulus duration, F(3,51) = 3.886, p = 0.0141; no interaction effect, F(3,51) = 0.9660, p =
0.4160).
At 10 months of age, female 5xFAD mice showed a significant decrease in accuracy
compared to controls (Figure 23A; RM-ANOVA, main effect of genotype, F(1,14) =
5.434, p = 0.0352; main effect of stimulus duration, F(3,42) = 23.85, p < 0.0001; no
interaction effect, F(3,42) = 1.530, p = 0.2208). However, no difference was observed
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Figure 22. Performance and response measures for 7 month-old 5xFAD Females
at the University of Western Ontario during the 5-CSRTT probe trials. Mice
were subject to a series of probe trial schedules and the average values of the sessions
are plotted. A, Mean accuracy. B, Mean omission. C, Mean correct response latency.
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward
collection latency (5xFAD females n=10, WT females n=9, data are mean ± SEM,
*p<0.05 and **p<0.01)
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Figure 23. Performance and response measures for 10 month-old 5xFAD Females
at the University of Western Ontario during the 5-CSRTT probe trials. Mice
were subject to a series of probe trial schedules and the average values of the sessions
are plotted.A, Mean accuracy. B, Mean omission. C, Mean correct response latency.
D, Mean premature responses. E, Mean perseverative correct. F, Mean reward
collection latency (5xFAD females n=9, WT females n=7, data are mean ± SEM)
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between genotypes in omissions (Figure 23B; RM-ANOVA, no effect of genotype, F(1,14)
= 1.987, p = 0.1805; main effect of stimulus duration, F(3,42) = 29.56, p < 0.0001; no
interaction effect, F(3,42) = 1.465, p = 0.2379), correct response latency (Figure 23C; RMANOVA, no effect of genotype, F(1,14) = 1.639, p = 0.2213; main effect of stimulus
duration, F(3,42) = 6.632, p = 0.0009; no interaction effect, F(3,42) = 0.8247, p = 0.4877),
premature responses (Figure 23D; RM-ANOVA, no effect of genotype, F(1,14) = 0.6063,
p = 0.4492; no effect of stimulus duration, F(3,42) = 0.9553, p = 0.4227; no interaction
effect, F(3,42) = 0.2637, p = 0.8512), perseverative correct responses (Figure 23E; RMANOVA, no effect of genotype, F(1,14) = 2.369, p = 0.1461; no effect of stimulus duration,
F(3,42) = 1.194, p = 0.3238; no interaction effect, F(3,42) = 0.0909, p = 0.9646), or reward
collection latency (Figure 23F; RM-ANOVA, no effect of genotype, F(1,14) = 1.875, p =
0.1925; no effect of stimulus duration, F(3,42) = 2257, p = 0.8780; no interaction effect,
F(3,42) = 0.6030, p = 0.6167).

3.7 Reproducibility of 5xFAD Data Between Sites
The 5xFAD mouse line was also run simultaneously at site 1 and site 2 in order to
determine whether the 5-CSRTT data are reproducible. Again, accuracy from the 10
month-old mice was analysed because this is where we observed the largest difference
between genotypes. Male wild-type mice displayed no difference in accuracy between
sites (Figure 24A; RM-ANOVA, no effect of genotype, F(1,20) = 1.191, p = 0.2881; main
effect of stimulus duration, F(3,60) = 36.22, p < 0.0001; no interaction effect, F(3,60) =
0.2995, p = 0.8256), nor did the 5xFAD mice (Figure 24B; RM-ANOVA, no effect of
genotype, F(1,21) = 1.133, p = 0.2992; main effect of stimulus duration, F(3,63) = 77.10, p <
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Figure 24. Comparison of the performance and response measures of 10 monthold 5xFAD and Wild-type Males and Females tested at the University of Western
Ontario (London) and at the University of Guelph (Guelph) during the 5-CSRTT
probe trials. Mice were subject to a series of probe trial schedules and the average
values of the sessions are plotted. A, Mean accuracy for WT males. B, Mean accuracy
for 5xFAD males from both sites. C, Mean accuracy for WT females. D, Mean
accuracy for 5xFAD females. (Data are mean ± SEM).
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0.0001; no interaction effect, F(3,63) = 0.7266, p = 0.5399). Likewise, 10 month-old wildtype females did not exhibit a difference in accuracy when compared between the two
sites (Figure 24C; RM-ANOVA, no effect of genotype, F(1,13) = 0.8213, p = 0.3785; main
effect of stimulus duration, F(3,39) = 57.62, p < 0.0001; no interaction effect, F(3,39) =
1.216, p = 0.3169). There was also no difference observed in the performance of the two
groups of 5xFAD females between sites (Figure 24D; RM-ANOVA, no effect of
genotype, F(1,17) = 1.826, p = 0.1943; main effect of stimulus duration, F(3,51) = 19.82, p <
0.0001; no interaction effect, F(3,51) = 1.546, p = 0.2094). The comparison of data for
many of the other relevant parameters also revealed very little differences between sites
(not shown). This suggests that data for the 5xFAD mouse line are also reproducible
between sites 1 and 2. We obtained data from Dr. Winters’ group and combined the
analysis to increase statistical power and define the most robust phenotypes.
Attention capacity of male 5xFAD mice (combining the data from both sites) was
analyzed. There was no difference in accuracy between 4.5 month-old 5xFAD males and
controls (Figure 25A; RM-ANOVA, no effect of genotype, F(1,37) = 0.0001, p = 0.9968;
main effect of stimulus duration, F(3,111) = 43.46, p < 0.0001; no interaction effect, F(3,111)
= 0.5811, p = 0.6286). In addition, no difference in genotypes were observed in
omissions (Figure 25B; RM-ANOVA, no effect of genotype, F(1,37) = 0.3821, p = 0.5403;
main effect of stimulus duration, F(3,111) = 81.32, p < 0.0001; no interaction effect, F(3,111)
= 1.268, p = 0.2889), correct response latency (Figure 25C; RM-ANOVA, no effect of
genotype, F(1,37) = 2.576, p = 0.1170; main effect of stimulus duration, F(3,111) = 4.981, p
= 0.0028; no interaction effect, F(3,111) = 0.3271, p = 0.8058), premature responses
(Figure 25D; RM-ANOVA, no effect of genotype, F(1,37) = 0.1064, p = 0.7461; main
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Figure 25. Performance and response measures of the combined data for 4.5
month-old 5xFAD Males at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (5xFAD males n=19, WT males n=20, data are mean ± SEM)
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effect of stimulus duration, F(3,111) = 3.400, p = 0.0203; no interaction effect, F(3,111) =
2.403, p = 0.0714), perseverative correct responses (Figure 25E; RM-ANOVA, no effect
of genotype, F(1,37) = 0.3285, p = 0.5700; main effect of stimulus duration, F(3,111) =
7.363, p = 0.0002; no interaction effect, F(3,111) = 0.5485, p = 0.6502), or reward
collection latency (Figure 25F; RM-ANOVA, no effect of genotype, F(1,37) = 0.2046, p =
0.6537; main effect of stimulus duration, F(3,111) = 0.4887, p = 0.6908; no interaction
effect, F(3,111) = 0.5517, p = 0.6480).
At 7 months, 5xFAD males from the combined data displayed a significant difference in
accuracy compared to age-matched controls (Figure 26A; RM-ANOVA, main effect of
genotype, F(1,43) = 0.5.658, p = 0.0219; main effect of stimulus duration, F(3,129) = 63.72, p
< 0.0001; no interaction effect, F(3,129) = 0.4193, p = 0.7394) but had no significant
change in omissions (Figure 26B; RM-ANOVA, no effect of genotype, F(1,43) = 1.862, p
= 0.1794; main effect of stimulus duration, F(3,129) = 61.63, p < 0.0001; no interaction
effect, F(3,129) = 0.4579, p = 0.7122). Combined data at 7 months did show male 5xFAD
mice to have significant difference in correct response latency compared to controls
(Figure 26C; RM-ANOVA, main effect of genotype, F(1,43) = 9.435, p = 0.0037; main
effect of stimulus duration, F(3,129) = 5.898, p = 0.0008; no interaction effect, F(3,129) =
0.3240, p = 0.8080). No difference between genotypes was observed in premature
responses (Figure 26D; RM-ANOVA, no effect of genotype, F(1,43) = 0.4497, p = 0.5061;
main effect of stimulus duration, F(3,129) = 2.875, p = 0.0388; no interaction effect, F(3,129)
= 0.7579, p = 0.5197). Also, combined data for 7 month-old 5xFAD males displayed a
difference compared to controls in perseverative correct responses (Figure 26E; RMANOVA, main effect of genotype, F(1,43) = 10.54, p = 0.0023; main effect of stimulus
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Figure 26. Performance and response measures of the combined data for 7
month-old 5xFAD Males at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (5xFAD males n=24, WT males n=21, data are mean ± SEM, *p<0.05 and
**p<0.01)
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duration, F(3,129) = 9.837, p < 0.0001; no interaction effect, F(3,129) = 2.265, p = 0.0841),
and decreased reward collection latency (Figure 26F; RM-ANOVA, main effect of
genotype, F(1,43) = 6.657, p = 0.0134; no effect of stimulus duration, F(3,129) = 1.354, p =
0.2599; no interaction effect, F(3,129) = 0.5902, p = 0.6255).
The combined data for 10 month-old 5xFAD males demonstrated increased deficits in
accuracy with both a genotype and interaction difference (Figure 27A; RM-ANOVA,
main effect of genotype, F(1,43) = 8.148, p = 0.0066; main effect of stimulus duration,
F(3,129) = 111.4, p < 0.0001; main interaction effect, F(3,129) = 3.474, p = 0.0181) and the
post-hoc analysis revealed a significantly lower accuracy at both the 0.8s and 0.6s
stimulus durations for the transgenic males compared to controls (Fig. 27A). In addition,
significant differences were observed between genotypes in omissions (Figure 27B; RMANOVA, main effect of genotype, F(1,43) = 7.570, p = 0.0087; main effect of stimulus
duration, F(3,129) = 50.52, p < 0.0001; no interaction effect, F(3,129) = 1.358, p = 0.2586),
and correct response latency (Figure 27C; RM-ANOVA, main effect of genotype, F(1,43)
= 21.20, p < 0.0001; main effect of stimulus duration, F(3,129) = 22.78, p < 0.0001; main
interaction effect, F(3,129) = 31.67, p = 0.0267). The 10 month-old male 5xFAD mice did
not show a difference in premature responses compared to controls in the combined data
(Figure 27D; RM-ANOVA, no effect of genotype, F(1,43) = 0.0244, p = 0.8765; main
effect of stimulus duration, F(3,129) = 6.549, p = 0.0004; no interaction effect, F(3,129) =
1.538, p = 0.2078). However, compared to age-matched controls, the performance of
5xFAD males did differ for perseverative correct (Figure 27E; RM-ANOVA, main effect
of genotype, F(1,43) = 11.19, p = 0.0017; main effect of stimulus duration, F(3,129) = 11.93,
p < 0.0001; no interaction effect, F(3,129) = 0.3469, p = 0.7914), and reward collection
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Figure 27. Performance and response measures of the combined data for 10
month-old 5xFAD Males at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (5xFAD males n=23, WT males n=22, data are mean ± SEM, **p<0.01 and
****p<0.0001)
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latency (Figure 27F; RM-ANOVA, main effect of genotype, F(1,43) = 8.621, p = 0.0053;
no effect of stimulus duration, F(3,129) = 1.237, p = 0.2989; no interaction effect, F(3,129) =
1.418, p = 0.2405).
The performance of the 5xFAD females (combined data from both sites) was analyzed
and revealed no differences in accuracy between the transgenic and wild-type controls at
4.5 months of age (Figure 28A; RM-ANOVA, no effect of genotype, F(1,42) = 0.5529, p =
0.4613; main effect of stimulus duration, F(3,126) = 44.61, p < 0.0001; no interaction
effect, F(3,126) = 0.8749, p = 0.4561). Similarly, no differences was observed between
genotypes in omissions (Figure 28B; RM-ANOVA, no effect of genotype, F(1,42) =
0.0902, p = 0.7654; main effect of stimulus duration, F(3,126) = 41.99, p < 0.0001; no
interaction effect, F(3,126) = 1.410, p = 0.2429), correct response latency (Figure 28C;
RM-ANOVA, no effect of genotype, F(1,42) = 0.4515, p = 0.5053; main effect of stimulus
duration, F(3,126) = 8.164, p < 0.0001; no interaction effect, F(3,126) = 0.6658, p = 0.5746),
premature responses (Figure 28D; ; RM-ANOVA, no effect of genotype, F(1,42) = 0.4112,
p = 0.5248; no effect of stimulus duration, F(3,126) = 1.906, p = 0.1320; no interaction
effect, F(3,126) = 0.4807, p = 0.6963), perseverative correct (Figure 28E; RM-ANOVA, no
effect of genotype, F(1,42) = 0.6653, p = 0.4193; main effect of stimulus duration, F(3,126) =
7.328, p = 0.0001; no interaction effect, F(3,126) = 0.1218, p = 0.9471), or reward
collection latency (Figure 28F; RM-ANOVA, no effect of genotype, F(1,42) = 2.952, p =
0.0931; no effect of stimulus duration, F(3,126) = 2.271, p = 0.0835; no interaction effect,
F(3,126) = 0.6320, p = 0.5957).
The combined data for 7 month-old 5xFAD females revealed a significantly decreased
accuracy compared to age-matched controls (Figure 29A; RM-ANOVA, main effect of
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Figure 28. Performance and response measures of the combined data for 4.5
month-old 5xFAD Females at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (5xFAD females n=22, WT females n=22, data are mean ± SEM)
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Figure 29. Performance and response measures of the combined data for 7
month-old 5xFAD Females at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (5xFAD females n=19, WT females n=20, data are mean ± SEM, *p<0.05,
**p<0.01 and ***p<0.001)
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genotype, F(1,37) = 6.260, p = 0.0169; main effect of stimulus duration, F(3,111) = 67.20, p
< 0.0001; no interaction effect, F(3,111) = 1.551, p = 0.2053). There were no differences
observed between genotypes in the combined data for omissions (Figure 29B; RMANOVA, no effect of genotype, F(1,37) = 1.692, p = 0.2014; main effect of stimulus
duration, F(3,111) = 46.59, p < 0.0001; no interaction effect, F(3,111) = 0.8721, p = 0.4579),
correct response latency (Figure 29C; RM-ANOVA, no effect of genotype, F(1,37) =
2.690, p = 0.1094; main effect of stimulus duration, F(3,111) = 3.767, p = 0.0128; no
interaction effect, F(3,111) = 3.306, p = 0.0529), or premature responses (Figure 29D; RMANOVA, no effect of genotype, F(1,37) = 1.314, p = 0.2589; no effect of stimulus duration,
F(3,111) = 2.078, p = 0.1072; no interaction effect, F(3,111) = 0.0798, p = 0.9709). However,
combined data for 7 month-old 5xFAD females did demonstrate significantly different
perseverative correct responses (Figure 29E; RM-ANOVA, main effect of genotype,
F(1,37) = 11.19, p = 0.0019; main effect of stimulus duration, F(3,111) = 7.327, p = 0.0002;
no interaction effect, F(3,111) = 0.2583, p = 0.8552), and reward collection latency
compared to controls (Figure 29F; RM-ANOVA, main effect of genotype, F(1,37) = 15.12,
p = 0.0004; no effect of stimulus duration, F(3,111) = 1.204, p = 0.3117; no interaction
effect, F(3,111) = 1.085, p = 0.3585).
Combined data for 10 month-old 5xFAD females displayed a difference in accuracy
compared age-matched controls (Figure 30A; RM-ANOVA, main effect of genotype,
F(1,32) = 9.415, p = 0.0044; main effect of stimulus duration, F(3,96) = 56.68, p < 0.0001;
no interaction effect, F(3,96) = 0.4453, p = 0.7212). In contrast, combined data for female
5xFAD mice suggest there was no difference in omission when compared to controls
(Figure 30B; RM-ANOVA, no effect of genotype, F(1,32) = 2.111, p = 0.1560; main effect
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Figure 30. Performance and response measures of the combined data for 10
month-old 5xFAD Females at the University of Western Ontario and at the
University of Guelph during the 5-CSRTT probe trials. Mice were subject to a
series of probe trial schedules and the average values of the sessions are plotted. A,
Mean accuracy. B, Mean omission. C, Mean correct response latency. D, Mean
premature responses. E, Mean perseverative correct. F, Mean reward collection
latency (5xFAD females n=19, WT females n=20, data are mean ± SEM, *p<0.05 and
**p<0.01)
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of stimulus duration, F(3,96) = 46.05, p < 0.0001; no interaction effect, F(3,96) = 3.649, p =
0.153), correct response latency (Figure 30C; RM-ANOVA, no effect of genotype, F(1,32)
= 0.6071, p = 0.4461; main effect of stimulus duration, F(3,96) = 9.548, p < 0.0001; no
interaction effect, F(3,96) = 1.157, p = 0.3301), or premature responses (Figure 30D; RMANOVA, no effect of genotype, F(1,32) = 0.5205, p = 0.4759; main effect of stimulus
duration, F(3,96) = 4.009, p = 0.0098; no interaction effect, F(3,96) = 0.3724, p = 0.7731).
However, combined data did reveal genotype differences in perseverative correct
responses (Figure 30E; RM-ANOVA, main effect of genotype, F(1,32) = 7.138, p =
0.0118; main effect of stimulus duration, F(3,96) = 4.766, p = 0.0039; no interaction effect,
F(3,96) = 0.6510, p = 0.5842), and reward collection latency (Figure 30F; RM-ANOVA,
main effect of genotype, F(1,32) = 6.787, p = 0.0138; no effect of stimulus duration, F(3,96)
= 0.3265, p = 0.8062; no interaction effect, F(3,96) = 0.6618, p = 0.5775).
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4

Discussion

4.1 Touchscreen systems diminish reproducibility problems
associated with animal behavioural testing
Traditional mouse behavioural testing is usually slow, not amenable to high-throughput
screening of a large number of animals and is far from being standardized. Unfortunately,
conventional cognitive behavioural tests for mouse models are subject to extreme
variation (Wahlsten et al., 2001, Wahlsten et al., 2003, Brown et al., 2009). The
touchscreen-based 5-CSRTT in this study helped to improve these problems by allowing
us to obtain replicable data between the two laboratories at site 1 and site 2.
The touchscreen systems gave us the opportunity to test a high number of animals daily
and increase our sample size, thus improving statistical power of experiments. Research
has shown that studies with a small number of subjects have a lower statistical power and
hence a decreased chance of detecting a true effect (Button et al., 2013). In addition,
research has revealed the average statistical power of studies in neuroscience is very low
(Button et al., 2013). The data between site 1 and site 2 showed minimal variation and
thus allowed us to combine the data within genotypes.
Traditional mouse behavioural testing also lacks translatable ability from the pre-clinical
to clinical setting. For instance, multiple promising pharmacological treatments observed
in animal models of AD failed to show similar results when tested in the clinic (Selkoe,
2012). The touchscreen systems utilized in this study are far more translatable to humans
than other traditional mouse behavioural tests, such as the Morris Water maze or the Ymaze task. Based on the human CANTAB systems, the 5-CSRTT on the mouse
touchscreen systems examine the same parameters as those observed in humans with AD
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or MCI, hence increasing the translational potential for research in mouse models of AD
(Bussey et al., 2008, Romberg et al., 2013a). The data obtained in this study help to
provide an important baseline for the onset and progression of attention deficits in the
3xTG and 5xFAD mouse lines for the testing potential pharmaceutical agents using the 5CSRTT in the future.

4.2 Basis of Attention Deficits in AD
Translation of data from mouse experiments to humans may also be improved if we were
to expand our scope in preclinical studies to include not only memory, but also other
relevant cognitive brain constructs such as attention. Individuals with AD have impaired
executive control, part of which is attention (Perry and Hodges, 1999, Baddeley et al.,
2001). Clinical observation of AD patients has revealed they have difficulty performing
simple tasks at a relatively early stage in the disease, often described easily distractible,
unable to concentrate and have difficulty with tasks that were previously easily
performed (Perry and Hodges, 1999). Recent work from Dr. Bussey and Dr. Saksida’s
lab has shown the 3xTG male mice, older than 10 months, have deficits in attention using
the 5-CSRTT on the touchscreen systems (Romberg et al., 2011). The results obtained in
this study for 3xTG males reproduce those observed by Dr. Bussey’s lab. Other work on
the TgCRND8 mouse model of AD has shown deficits in attention during the latter stages
of life (Romberg et al., 2011, Romberg et al., 2013b). Our study demonstrates a
systematic deficit in 5-CSRTT performance with age in both the 3xTG and 5xFAD
mouse models of AD.
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Current evidence suggests that attention is the first non-memory domain to be affected in
AD before deficits in visuospatial functions and language are observed (Perry and
Hodges, 1999, Romberg et al., 2013a). Hence, recognizing the onset of attention deficits
may help in the early diagnosis of AD, before it progresses to other cognitive domains.
This is an important step in testing potential pharmacological interventions that act early
and prevent the progression of AD. Different mouse models of AD have attention deficits
at different ages depending on a number of factors including the types of mutations the
mice carry (Webster et al., 2014). Our study demonstrated that the onset of attention
deficits in the 3xTG and 5xFAD mouse models differs, with 4 and 7 months of age
respectively. More importantly, this helps establish a baseline for the onset of AD-like
attention deficits in these two mouse models of AD. The majority of behavioural studies
using these or other mouse models of AD test cognitive functions when the mice are in
later stages of life, in order to mimic the symptoms of AD seen in humans (Romberg et
al., 2011, Romberg et al., 2013b). Unfortunately, not only does this increase the costs of
maintaining mice as they age, but it also decreases the success of potential therapeutics as
the AD-like pathology may be too far advanced in the older mice.

4.3 3xTG Mice Show Attention Deficits Earlier than 5xFAD
We show that both the 3xTG and 5xFAD mouse lines exhibit attention deficits using the
5-CSRTT. The 3xTG male and female mice showed deficits in accuracy, the main
measure of attention in this task, at 4.5 months of age and throughout the other two time
points at 7 months and 10 months. On the other hand, the 5xFAD male and female mice
showed deficits in accuracy starting at 7 months and more statistically significant deficits
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at 10 months, but showed no difference at 4.5 months. This difference in performance
could be a result of the additional tau mutation the 3xTG mice carry. The 5xFAD mice
have three mutations on the APP gene (APPSWE, APPFl, APPLON) as well as two
mutations on the PSEN1 gene (M146L and L286V) (Oakley et al., 2006). The 3xTG
mice on the other hand have one mutation for APP (APPSWE), one on PSEN1 (M146L)
and a mutation on the tau transgene (P301L) (Oddo et al., 2003b). The 3xTG mice show
accumulation of both plaques and tangles in AD relevant brain regions as well as loss in
synaptic plasticity and cholinergic receptors (Billings et al., 2005). In the 3xTG mice, the
first detectable pathology is the development of intracellular Aβ at 3 months followed by
detection of both extracellular Aβ plaques and hyperphosphorylated tau in the
hippocampus at 6 months (Billings et al., 2005, Mastrangelo and Bowers, 2008). The
5xFAD mice however, have been shown to have intracellular Aβ detectable at 1.5 months
and extracellular plaques at 2 months (Oakley et al., 2006).
Although many studies have suggested that Aβ is the initiating factor of AD and tau
dysfunction is a downstream factor to Aβ aggregation (Hardy and Allsop, 1991, Hardy
and Selkoe, 2002) other studies have suggested that tau interacts with Aβ and accelerates
the progression of AD (Oddo et al., 2006a). Numerous studies have also shown that
soluble oligomers are the most toxic form of Aβ to neurons (Harper et al., 1997, Walsh
and Selkoe, 2007) and several others have shown that soluble tau oligomers may also be
more toxic in AD (Berger et al., 2007, Roberson et al., 2007, Lasagna-Reeves et al.,
2011, Castillo-Carranza et al., 2014). More recent studies have also revealed that soluble
tau species including prefibrillar, oligomeric and prefilament forms are more toxic in AD
than the hallmark NFTs, which may in fact have a more protective role (Bretteville and
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Planel, 2008, Cowan and Mudher, 2013). Hence, in the 3xTG mice, oligomeric tau
protein may be leading to the early deficits in attention observed in the 5-CSRTT.
The AD-like attention deficits observed in both the male and female 5xFAD mice at 7
months and onwards can be attributed to the mutations in APP and PSEN-1 that lead to
Aβ plaques. Attentional control, part of executive functions, is controlled by a myriad of
cortical and subcortical regions. The 5xFAD mice have been shown to have Aβ
accumulation in cortical regions by 6 months of age, followed by synaptic degeneration
and loss of neurons by 9 months (Oakley et al., 2006, Bilkei-Gorzo, 2014). This
coincides with the deficits in attention we observed in the 5xFAD mice, first appearing at
7 months and deteriorating significantly at 10 months, for both sexes. Thus, the deficits in
attention observed in the 5xFAD mouse line suggests they are a direct result of Aβ
accumulating in the cortex.

4.4 Other Cognitive deficits in AD-mouse models revealed
by the 5-CSRTT
Similar to the attention deficits observed, the 3xTG mice also showed very significant
deficits in correct response latency throughout all three probe trials. Correct response
latency is the amount of time a mouse takes to touch the screen after the onset of a
stimulus. This is a measure of cognitive processing speed (Romberg et al., 2011) and the
3xTG mice took significantly longer from the first time point of 4.5 months and onwards.
The 5xFAD mice also showed deficits in correct response latency but these were only
present during the later time points. The cognitive processing of the 3xTG mice so early
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in life can be again attributed to the presence of the tau (P301L) mutation. Recent studies
have shown that levels of hyperphosphorylated tau protein, NFTs, but not Aβ load,
correlates strongly with cognition in AD (Giacobini and Gold, 2013). In one study, APP
mice that showed cognitive deficits were crossed with tau knockout mice to make a new
mouse mode that lower levels of tau. This had no effect on the development of Aβ
pathology; however, it did prevent the cognitive deficits that were seen originally in the
APP mice (Roberson et al., 2007). Findings in studies using transgenic animals carrying
tau mutations also seem more closely aligned with human AD studies (LaFerla and
Green, 2012). The 5xFAD mice also showed deficits in correct response latencies but
during the last probe trials. Evidence from previous research has suggested that Aβ
formation can drive tau pathology in patients with AD (Handoko et al., 2013). Transgenic
mice that overexpress mutated forms of APP, like the 5xFAD mice, are the most
commonly used animal models of AD in research. Despite extensive Aβ accumulation,
these mice do not develop NFTs, but research has shown that they can exhibit elevated
levels of hyperphosphorylated tau (Oddo et al., 2006b). This may be occurring in the
5xFAD mice as well, in the later stages of their life, after extensive Aβ plaque
accumulation has occurred leading to the deficits in cognitive processing speed that we
observed during the 10 months time point.
On the other hand, the 5xFAD mice also demonstrated significant differences in
preservative correct and reward collection latency during the 10 months probe trial.
Although food restricted, these mice showed a lack of motivation (higher reward
collection latency) and were more placid (decreased preservative correct) compared to
their age-matched wild-type littermates. These deficits at 10 months, along with the
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deficits in accuracy and correct response latency, may be occurring due to the widespread
Aβ accumulation that leads to neurodegeneration in these mice starting at 9 months of
age (Oakley et al., 2006). As previously shown, the 5xFAD mice have extensive Aβ
deposition in the cortex, subiculum, and hippocampus from 9 months onwards (Oakley et
al., 2006). At 9 months of age, 5xFAD transgenic mice have only 75% of the neurons that
age-matched controls possess due to synaptic degeneration (Oakley et al., 2006). Hence,
this may be the driving factor to the cognitive deficits observed in this mouse line.

4.5 Male 3xTG and 5xFAD mice show increased attention
deficits with age compared to females
The male 3xTG and 5xFAD mice showed greater deficits in attention with age compared
to females. At the last time point of 10 months, the males from both sites demonstrated
not only deficits in accuracy, but also in omissions. The females on the other hand did not
show any difference in omission. Although accuracy is the main measure of attention in
the 5-CSRTT, differences in omission can also represent deficits in attention as it
determines whether there is a complete failure to pay attention the stimulus displayed on
the screen (Romberg et al., 2013a). Thus, the males from both mouse lines seem to have
greater AD-like cognitive deficits in attention at this age than females.
Research has suggested that estrogen, the female sex hormone, can play a protective role
in the brain of females against AD, and loss of estrogen during menopause leads to
deficits in brain metabolism leading to the hallmark lesions seen in the disease (Long et
al., 2012). Estrogen has also been shown to have a critical role in neurogenesis in various
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regions including the hippocampus and other subcortical regions leading to the
generation of neurons that contribute to region-specific learning and memory (Galea et
al., 2013). Several studies have provided insight into the importance of estrogen on
neuronal morphology and synaptic plasticity in the CA1 region of the hippocampus
(Mukai et al., 2010, Hojo et al., 2011, Ooishi et al., 2012, Spencer-Segal et al., 2012).
Moreover, estrogen reduces levels of Aβ in the presence of pathological triggers
(Anastasio, 2013). Research has also shown that estrogen can help reduce levels of Aβ
production by decreasing BACE1 enzyme levels, and increasing Aβ clearance by
stimulation of microglia degradation and phagocytosis as well as increasing levels of
other enzymes that are involved in Aβ degradation (Singh et al., 1999). Additionally,
studies have also shown that estrogen has a role in decreasing levels of
hyperphosphorylated tau by activating kinases and phosphatases such as the Wnt, GSK3β and PKA pathways (Zhang et al., 2008). The loss in estrogen during menopause in
females has been suggested to account for the increased susceptibility to AD compared to
males (Yue et al., 2005, Li et al., 2013). Furthermore, one study demonstrated decreased
levels of estrogen in the CSF of AD patients providing additional confirmation of its role
in the disease (Schonknecht et al., 2001).
Moreover, in a recent study that used aged female 3xTG mice, there was an increase in
AD pathology in transgenic mice who had an overiectomy, leading to reduced levels of
estrogen and other gonadotropins, compared to age-matched transgenic females that did
not (Palm et al., 2014). In addition, research shows that levels of estrogen and
testosterone decrease steadily with age in both males and pre-menopausal females
(Ferrini and Barrett-Connor, 1998). Thus, the attention deficits in the mice at 10 months
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may also be due to a slight decrease in levels of estrogen with age, leading to an increase
in AD-like pathology. Overall, our study suggests estrogen may be playing a protective
role in both the 3xTG and 5xFAD female mice. The lower levels of estrogen in males
may be contributing to greater AD-like pathology thus leading to greater attention deficits
with age.

4.6 Conclusion
In summary, we provide a good baseline for the onset and progression of AD-like
attention deficits in both the 3xTG and 5xFAD mouse lines. Due to their three mutations
that lead to both Aβ plaques as well as tau NFTs, both the male and female 3xTG mice
showed deficits in attention during the first time point and onwards of this longitudinal
study. The 5xFAD males and females on the other hand, with their five additive
mutations that lead an accelerated rate of amyloidosis, showed deficits from the 7 months
time point and onwards. In addition, the majority of data was reproduced between site 1
and site 2, attesting to the reliability of the touchscreen systems used in this study.
Transgenic male mice from both lines showed greater deficits in attention with age
compared to female mice.

4.7 Future Directions
Further behavioural testing will be done using both the 3xTG and 5xFAD mice on the
touchscreen systems to determine if and when they have deficits in other cognitive
domains. The PAL task will be utilized to test for spatial memory deficits and the PD task
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will be used to evaluate whether the mice have deficits in extinction learning. In addition,
another mouse model of AD, the APP/PSEN1 male and female mice will be used on all
three touchscreen tasks (5-CSRTT, PAL, and PD) to determine whether they also display
AD-like cognitive symptoms. Furthermore, we plan on imaging the brains of all three
mouse lines at the three probe trial time points used in the 5-CSRTT in order to determine
the extent of AD-like plaques and tangles these mice display. In the near future, we also
plan on testing potential pharmacological agents that may help treat the cognitive
symptoms associated with AD using the touchscreen systems and the baselines
established in order to accelerate this process.

	
  	
  

98

References
Anastasio TJ (2013) Exploring the contribution of estrogen to amyloid-Beta regulation: a
novel multifactorial computational modeling approach. Frontiers in pharmacology
4:16.
Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P, DiCarlo
G, Wilcock D, Morgan D (2001a) Behavioral assessment of Alzheimer's
transgenic mice following long-term Abeta vaccination: task specificity and
correlations between Abeta deposition and spatial memory. DNA and cell biology
20:737-744.
Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM
(2001b) Progressive, age-related behavioral impairments in transgenic mice
carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain
research 891:42-53.
Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, Garcia MF
(2004) Multi-metric behavioral comparison of APPsw and P301L models for
Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in
forebrain. Brain research 1012:29-41.
Artero S, Ritchie K (2003) The detection of mild cognitive impairment in the general
practice setting. Aging & mental health 7:251-258.
Baddeley AD, Baddeley HA, Bucks RS, Wilcock GK (2001) Attentional control in
Alzheimer's disease. Brain 124:1492-1508.
Baglietto-Vargas D, Chen Y, Suh D, Ager RR, Rodriguez-Ortiz CJ, Medeiros R, Myczek
K, Green KN, Baram TZ, LaFerla FM (2015) Short-term modern life-like stress
exacerbates Abeta-pathology and synapse loss in 3xTg-AD mice. Journal of
neurochemistry.
Beck LH, Bransome ED, Jr., Mirsky AF, Rosvold HE, Sarason I (1956) A continuous
performance test of brain damage. Journal of consulting psychology 20:343-350.
Becker RE, Greig NH, Giacobini E (2008) Why do so many drugs for Alzheimer's
disease fail in development? Time for new methods and new practices? Journal of
Alzheimer's disease : JAD 15:303-325.
Bennett DA (2007) Editorial comment on 'Prevalence of dementia in the United States:
the aging, demographics, and memory study' by Plassman et al.
Neuroepidemiology 29:133-135.
Bentley P, Driver J, Dolan RJ (2008) Cholinesterase inhibition modulates visual and
attentional brain responses in Alzheimer's disease and health. Brain : a journal of
neurology 131:409-424.

99

Berchtold NC, Cotman CW (1998) Evolution in the conceptualization of dementia and
Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiology of aging
19:173-189.
Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K,
Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C
(2007) Accumulation of pathological tau species and memory loss in a
conditional model of tauopathy. The Journal of neuroscience : the official journal
of the Society for Neuroscience 27:3650-3662.
Bilkei-Gorzo A (2014) Genetic mouse models of brain ageing and Alzheimer's disease.
Pharmacology & therapeutics 142:244-257.
Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta
causes the onset of early Alzheimer's disease-related cognitive deficits in
transgenic mice. Neuron 45:675-688.
Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. The Cochrane database
of systematic reviews CD005593.
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403.
Boller F, Forbes MM (1998) History of dementia and dementia in history: an overview.
Journal of the neurological sciences 158:125-133.
Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994) Regional
distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of
elderly patients: a quantitative evaluation of a one-year autopsy population from a
geriatric hospital. Cerebral cortex 4:138-150.
Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes
and indices of hypoxia in senile dementia and other abiotrophies. Brain : a journal
of neurology 99:459-496.
Braak H, Braak E (1991) Demonstration of amyloid deposits and neurofibrillary changes
in whole brain sections. Brain pathology 1:213-216.
Bracco L, Bessi V, Padiglioni S, Marini S, Pepeu G (2014) Do cholinesterase inhibitors
act primarily on attention deficit? A naturalistic study in Alzheimer's disease
patients. Journal of Alzheimer's disease : JAD 40:737-742.
Bretteville A, Planel E (2008) Tau aggregates: toxic, inert, or protective species? Journal
of Alzheimer's disease : JAD 14:431-436.
Brown SD, Wurst W, Kuhn R, Hancock JM (2009) The functional annotation of
mammalian genomes: the challenge of phenotyping. Annual review of genetics
43:305-333.

100

Burns A, Iliffe S (2009) Alzheimer's disease. Bmj 338:b158.
Bussey TJ, Holmes A, Lyon L, Mar AC, McAllister KA, Nithianantharajah J, Oomen
CA, Saksida LM (2012) New translational assays for preclinical modelling of
cognition in schizophrenia: the touchscreen testing method for mice and rats.
Neuropharmacology 62:1191-1203.
Bussey TJ, Padain TL, Skillings EA, Winters BD, Morton AJ, Saksida LM (2008) The
touchscreen cognitive testing method for rodents: how to get the best out of your
rat. Learning & memory 15:516-523.
Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafo MR
(2013) Power failure: why small sample size undermines the reliability of
neuroscience. Nature reviews Neuroscience 14:365-376.
Carli M, Robbins TW, Evenden JL, Everitt BJ (1983) Effects of lesions to ascending
noradrenergic neurones on performance of a 5-choice serial reaction task in rats;
implications for theories of dorsal noradrenergic bundle function based on
selective attention and arousal. Behavioural brain research 9:361-380.
Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves
CA, Kayed R (2014) Specific targeting of tau oligomers in Htau mice prevents
cognitive impairment and tau toxicity following injection with brain-derived tau
oligomeric seeds. Journal of Alzheimer's disease : JAD 40 Suppl 1:S97-S111.
Chun W, Johnson GV (2007) The role of tau phosphorylation and cleavage in neuronal
cell death. Frontiers in bioscience : a journal and virtual library 12:733-756.
Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla
FM (2007) Age-dependent sexual dimorphism in cognition and stress response in
the 3xTg-AD mice. Neurobiology of disease 28:76-82.
Cowan CM, Mudher A (2013) Are tau aggregates toxic or protective in tauopathies?
Frontiers in neurology 4:114.
Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's
disease. Lancet 2:1403.
De Strooper B (2007) Loss-of-function presenilin mutations in Alzheimer disease.
Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO
reports 8:141-146.
De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH,
Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R (1999) A presenilin-1dependent gamma-secretase-like protease mediates release of Notch intracellular
domain. Nature 398:518-522.

101

Delacourt C, Herigault S, Delclaux C, Poncin A, Levame M, Harf A, Saudubray F,
Lafuma C (2002) Protection against acute lung injury by intravenous or
intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase
inhibitor. American journal of respiratory cell and molecular biology 26:290-297.
Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ (2009)
Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities
in brain myelination patterns prior to appearance of amyloid and tau pathology.
Glia 57:54-65.
Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. A
relationship to aging? Archives of neurology 30:113-121.
Duncan J (2006) EPS Mid-Career Award 2004: brain mechanisms of attention. Quarterly
journal of experimental psychology 59:2-27.
Duyckaerts C, Perruchini C, Lebouvier T, Potier MC (2008) [The lesions of Alzheimer's
disease: which therapeutic perspectives?]. Bulletin de l'Academie nationale de
medecine 192:303-318; discussion 318-321.
Eckman CB, Mehta ND, Crook R, Perez-tur J, Prihar G, Pfeiffer E, Graff-Radford N,
Hinder P, Yager D, Zenk B, Refolo LM, Prada CM, Younkin SG, Hutton M,
Hardy J (1997) A new pathogenic mutation in the APP gene (I716V) increases the
relative proportion of A beta 42(43). Human molecular genetics 6:2087-2089.
Ferrini RL, Barrett-Connor E (1998) Sex hormones and age: a cross-sectional study of
testosterone and estradiol and their bioavailable fractions in community-dwelling
men. American journal of epidemiology 147:750-754.
Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of
Alzheimer's disease: a review of progress. Journal of neurology, neurosurgery,
and psychiatry 66:137-147.
Galea LA, Wainwright SR, Roes MM, Duarte-Guterman P, Chow C, Hamson DK (2013)
Sex, hormones and neurogenesis in the hippocampus: hormonal modulation of
neurogenesis and potential functional implications. Journal of neuroendocrinology
25:1039-1061.
Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST (2005) Alzheimer disease and
mortality: a 15-year epidemiological study. Archives of neurology 62:779-784.
Giacobini E, Gold G (2013) Alzheimer disease therapy--moving from amyloid-beta to
tau. Nature reviews Neurology 9:677-686.
Girard SD, Jacquet M, Baranger K, Migliorati M, Escoffier G, Bernard A, Khrestchatisky
M, Feron F, Rivera S, Roman FS, Marchetti E (2014) Onset of hippocampusdependent memory impairments in 5XFAD transgenic mouse model of
Alzheimer's disease. Hippocampus 24:762-772.

102

Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L,
Haynes A, Irving N, James L, et al. (1991) Segregation of a missense mutation in
the amyloid precursor protein gene with familial Alzheimer's disease. Nature
349:704-706.
Gotz J, Schild A, Hoerndli F, Pennanen L (2004) Amyloid-induced neurofibrillary tangle
formation in Alzheimer's disease: insight from transgenic mouse and tissueculture models. International journal of developmental neuroscience : the official
journal of the International Society for Developmental Neuroscience 22:453-465.
Gray EG, Paula-Barbosa M, Roher A (1987) Alzheimer's disease: paired helical filaments
and cytomembranes. Neuropathology and applied neurobiology 13:91-110.
Greenson LJaH (1987) About a peculiar disease of the cerebral cortex. By Alois
Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson). Alzheimer disease
and associated disorders 1:3-8.
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C,
Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T,
Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell
J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis G
(2013) TREM2 variants in Alzheimer's disease. The New England journal of
medicine 368:117-127.
Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans
R, Smith-Gamble V, Unverzagt FW, Shen J, Hendrie H (2006) Cholesterol,
APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian
Yoruba. Neurology 66:223-227.
Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH (2013)
Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid
from cognitively normal older adults. JAMA neurology 70:594-599.
Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of
Alzheimer's disease. Trends in pharmacological sciences 12:383-388.
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and
problems on the road to therapeutics. Science 297:353-356.
Harper JD, Wong SS, Lieber CM, Lansbury PT (1997) Observation of metastable Abeta
amyloid protofibrils by atomic force microscopy. Chemistry & biology 4:119125.
Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL,
Dotti CG, Unsicker K, Beyreuther K (1997) Distinct sites of intracellular
production for Alzheimer's disease A beta40/42 amyloid peptides. Nature
medicine 3:1016-1020.

103

Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA (2001) Is the risk of
developing Alzheimer's disease greater for women than for men? American
journal of epidemiology 153:132-136.
Herbert MK, Aerts MB, Kuiperij HB, Claassen JA, Spies PE, Esselink RA, Bloem BR,
Verbeek MM (2014) Addition of MHPG to Alzheimer's disease biomarkers
improves differentiation of dementia with Lewy bodies from Alzheimer's disease
but not other dementias. Alzheimer's & dementia : the journal of the Alzheimer's
Association 10:448-455 e442.
Hernandez F, Avila J (2007) Tauopathies. Cellular and molecular life sciences : CMLS
64:2219-2233.
Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F,
Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla
FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka
Y (2008) Females exhibit more extensive amyloid, but not tau, pathology in an
Alzheimer transgenic model. Brain research 1216:92-103.
Hojo Y, Higo S, Kawato S, Hatanaka Y, Ooishi Y, Murakami G, Ishii H, Komatsuzaki Y,
Ogiue-Ikeda M, Mukai H, Kimoto T (2011) Hippocampal synthesis of sex
steroids and corticosteroids: essential for modulation of synaptic plasticity.
Frontiers in endocrinology 2:43.
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I,
Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM,
Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type
phenotype in transgenic mice carrying both mutant amyloid precursor protein and
presenilin 1 transgenes. Nature medicine 4:97-100.
Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D (1999) Behavioral
changes in transgenic mice expressing both amyloid precursor protein and
presenilin-1 mutations: lack of association with amyloid deposits. Behavior
genetics 29:177-185.
Hooper NM (2005) Roles of proteolysis and lipid rafts in the processing of the amyloid
precursor protein and prion protein. Biochemical Society transactions 33:335-338.
Horner AE, Heath CJ, Hvoslef-Eide M, Kent BA, Kim CH, Nilsson SR, Alsio J, Oomen
CA, Holmes A, Saksida LM, Bussey TJ (2013) The touchscreen operant platform
for testing learning and memory in rats and mice. Nature protocols 8:1961-1984.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G
(1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in
transgenic mice. Science 274:99-102.
Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell
148:1204-1222.

104

Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B,
Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in
Alzheimer disease and other tauopathies. Biochimica et biophysica acta
1739:198-210.
Jarrett JT, Berger EP, Lansbury PT, Jr. (1993) The carboxy terminus of the beta amyloid
protein is critical for the seeding of amyloid formation: implications for the
pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697.
Jones SE, Jomary C (2002) Clusterin. The international journal of biochemistry & cell
biology 34:427-431.
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S,
Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen
OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA,
van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of
TREM2 associated with the risk of Alzheimer's disease. The New England
journal of medicine 368:107-116.
Junkkila J, Oja S, Laine M, Karrasch M (2012) Applicability of the CANTAB-PAL
computerized memory test in identifying amnestic mild cognitive impairment and
Alzheimer's disease. Dementia and geriatric cognitive disorders 34:83-89.
Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL,
Klein WL (2007) Abeta oligomer-induced aberrations in synapse composition,
shape, and density provide a molecular basis for loss of connectivity in
Alzheimer's disease. The Journal of neuroscience : the official journal of the
Society for Neuroscience 27:796-807.
LaFerla FM, Green KN (2012) Animal models of Alzheimer disease. Cold Spring Harbor
perspectives in medicine 2.
Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano
AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones
N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN,
Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A,
Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr
C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S,
Letenneur L, Moron FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM,
Fievet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, BarbergerGateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S,
Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo
A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta G, Proitsi P,
Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC,
Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, European
Alzheimer's Disease I, Genetic, Environmental Risk in Alzheimer's D,
Alzheimer's Disease Genetic C, Cohorts for H, Aging Research in Genomic E,

105

Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M,
Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L,
Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V,
Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin
C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O,
O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Jr.,
Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P,
Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA,
Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS,
Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt
R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nothen
MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, PericakVance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina
V, Seshadri S, Williams J, Schellenberg GD, Amouyel P (2013) Meta-analysis of
74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
Nature genetics 45:1452-1458.
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE,
Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA,
Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are
potent central nervous system neurotoxins. Proceedings of the National Academy
of Sciences of the United States of America 95:6448-6453.
Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal
RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE,
Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW,
Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod
MR, McCall JM, Moxley RT, 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD,
Steward O, Unger E, Utz U, Silberberg SD (2012) A call for transparent reporting
to optimize the predictive value of preclinical research. Nature 490:187-191.
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R
(2011) Tau oligomers impair memory and induce synaptic and mitochondrial
dysfunction in wild-type mice. Molecular neurodegeneration 6:39.
Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B,
Schlessinger J (1995) Protein tyrosine kinase PYK2 involved in Ca(2+)-induced
regulation of ion channel and MAP kinase functions. Nature 376:737-745.
Li R, He P, Cui J, Staufenbiel M, Harada N, Shen Y (2013) Brain endogenous estrogen
levels determine responses to estrogen replacement therapy via regulation of
BACE1 and NEP in female Alzheimer's transgenic mice. Molecular neurobiology
47:857-867.
Long J, He P, Shen Y, Li R (2012) New evidence of mitochondria dysfunction in the
female Alzheimer's disease brain: deficiency of estrogen receptor-beta. Journal of
Alzheimer's disease : JAD 30:545-558.

106

Lott IT, Head E (2005) Alzheimer disease and Down syndrome: factors in pathogenesis.
Neurobiology of aging 26:383-389.
Maccioni RB, Cambiazo V (1995) Role of microtubule-associated proteins in the control
of microtubule assembly. Physiological reviews 75:835-864.
Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and
therapeutic target in neuropathology, including Alzheimer's disease. Proceedings
of the National Academy of Sciences of the United States of America 103:56445651.
Mar AC, Horner AE, Nilsson SR, Alsio J, Kent BA, Kim CH, Holmes A, Saksida LM,
Bussey TJ (2013) The touchscreen operant platform for assessing executive
function in rats and mice. Nature protocols 8:1985-2005.
Massoulie J, Pezzementi L, Bon S, Krejci E, Vallette FM (1993) Molecular and cellular
biology of cholinesterases. Progress in neurobiology 41:31-91.
Mastrangelo MA, Bowers WJ (2008) Detailed immunohistochemical characterization of
temporal and spatial progression of Alzheimer's disease-related pathologies in
male triple-transgenic mice. BMC neuroscience 9:81.
McDonald MP, Overmier JB (1998) Present imperfect: a critical review of animal models
of the mnemonic impairments in Alzheimer's disease. Neuroscience and
biobehavioral reviews 22:99-120.
McGuinness B, Barrett SL, Craig D, Lawson J, Passmore AP (2010) Attention deficits in
Alzheimer's disease and vascular dementia. Journal of neurology, neurosurgery,
and psychiatry 81:157-159.
Molsa PK, Marttila RJ, Rinne UK (1986) Survival and cause of death in Alzheimer's
disease and multi-infarct dementia. Acta neurologica Scandinavica 74:103-107.
Molsa PK, Marttila RJ, Rinne UK (1995) Long-term survival and predictors of mortality
in Alzheimer's disease and multi-infarct dementia. Acta neurologica Scandinavica
91:159-164.
Monsell S (2003) Task switching. Trends in cognitive sciences 7:134-140.
Mori T, Koyama N, Guillot-Sestier MV, Tan J, Town T (2013) Ferulic acid is a
nutraceutical beta-secretase modulator that improves behavioral impairment and
alzheimer-like pathology in transgenic mice. PloS one 8:e55774.
Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid beta-protein: synaptic and network
dysfunction. Cold Spring Harbor perspectives in medicine 2:a006338.
Muir JL, Everitt BJ, Robbins TW (1996) The cerebral cortex of the rat and visual
attentional function: dissociable effects of mediofrontal, cingulate, anterior

107

dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task.
Cerebral cortex 6:470-481.
Mukai H, Kimoto T, Hojo Y, Kawato S, Murakami G, Higo S, Hatanaka Y, Ogiue-Ikeda
M (2010) Modulation of synaptic plasticity by brain estrogen in the hippocampus.
Biochimica et biophysica acta 1800:1030-1044.
Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992)
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the Nterminus of beta-amyloid. Nature genetics 1:345-347.
Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, Brown M, Martin
B, Iyun T, Maudsley S, Clark RF, Mattson MP (2007) Prophylactic treatment
with paroxetine ameliorates behavioral deficits and retards the development of
amyloid and tau pathologies in 3xTgAD mice. Experimental neurology 205:166176.
Nilsson L, Nordberg A, Hardy J, Wester P, Winblad B (1986) Physostigmine restores
3H-acetylcholine efflux from Alzheimer brain slices to normal level. Journal of
neural transmission 67:275-285.
Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M,
Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid
aggregates, neurodegeneration, and neuron loss in transgenic mice with five
familial Alzheimer's disease mutations: potential factors in amyloid plaque
formation. The Journal of neuroscience : the official journal of the Society for
Neuroscience 26:10129-10140.
Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003a) Amyloid deposition
precedes tangle formation in a triple transgenic model of Alzheimer's disease.
Neurobiology of aging 24:1063-1070.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R,
Mattson MP, Akbari Y, LaFerla FM (2003b) Triple-transgenic model of
Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic
dysfunction. Neuron 39:409-421.
Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM (2006a)
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of
Alzheimer disease. A link between Abeta and tau pathology. The Journal of
biological chemistry 281:1599-1604.
Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM (2006b)
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates
cognitive decline in transgenic mice with plaques and tangles. The Journal of
biological chemistry 281:39413-39423.

108

Ohnishi S, Takano K (2004) Amyloid fibrils from the viewpoint of protein folding.
Cellular and molecular life sciences : CMLS 61:511-524.
Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF
(2006) Temporal memory deficits in Alzheimer's mouse models: rescue by
genetic deletion of BACE1. The European journal of neuroscience 23:251-260.
Ooishi Y, Kawato S, Hojo Y, Hatanaka Y, Higo S, Murakami G, Komatsuzaki Y, OgiueIkeda M, Kimoto T, Mukai H (2012) Modulation of synaptic plasticity in the
hippocampus by hippocampus-derived estrogen and androgen. The Journal of
steroid biochemistry and molecular biology 131:37-51.
Organization WH (2012) Dementia Fact Sheet N362.
Oules B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, PaterliniBrechot P, Trebak M, Checler F, Benfenati F, Chami M (2012) Ryanodine
receptor blockade reduces amyloid-beta load and memory impairments in Tg2576
mouse model of Alzheimer disease. The Journal of neuroscience : the official
journal of the Society for Neuroscience 32:11820-11834.
Palm R, Chang J, Blair J, Garcia-Mesa Y, Lee HG, Castellani RJ, Smith MA, Zhu X,
Casadesus G (2014) Down-regulation of serum gonadotropins but not estrogen
replacement improves cognition in aged-ovariectomized 3xTg AD female mice.
Journal of neurochemistry 130:115-125.
Pepeu G, Giovannini MG, Bracco L (2013) Effect of cholinesterase inhibitors on
attention. Chemico-biological interactions 203:361-364.
Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter
enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic
acid decarboxylase activities in necropsy brain tissue. Journal of the neurological
sciences 34:247-265.
Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978)
Correlation of cholinergic abnormalities with senile plaques and mental test
scores in senile dementia. British medical journal 2:1457-1459.
Perry RJ, Hodges JR (1999) Attention and executive deficits in Alzheimer's disease. A
critical review. Brain : a journal of neurology 122 ( Pt 3):383-404.
Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto
L, Halonen P, Kontula K (1995) Apolipoprotein E, dementia, and cortical
deposition of beta-amyloid protein. The New England journal of medicine
333:1242-1247.
Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (2006) Synapse
formation and function is modulated by the amyloid precursor protein. The

109

Journal of neuroscience : the official journal of the Society for Neuroscience
26:7212-7221.
Robbins TW (1997) Arousal systems and attentional processes. Biological psychology
45:57-71.
Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology
and functional neurochemistry. Psychopharmacology 163:362-380.
Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ,
Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced
deficits in an Alzheimer's disease mouse model. Science 316:750-754.
Romberg C, Bussey TJ, Saksida LM (2013a) Paying more attention to attention: towards
more comprehensive cognitive translation using mouse models of Alzheimer's
disease. Brain research bulletin 92:49-55.
Romberg C, Horner AE, Bussey TJ, Saksida LM (2013b) A touch screen-automated
cognitive test battery reveals impaired attention, memory abnormalities, and
increased response inhibition in the TgCRND8 mouse model of Alzheimer's
disease. Neurobiology of aging 34:731-744.
Romberg C, Mattson MP, Mughal MR, Bussey TJ, Saksida LM (2011) Impaired
attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by
donepezil (Aricept). The Journal of neuroscience : the official journal of the
Society for Neuroscience 31:3500-3507.
Rylett RJ, Ball MJ, Colhoun EH (1983) Evidence for high affinity choline transport in
synaptosomes prepared from hippocampus and neocortex of patients with
Alzheimer's disease. Brain research 289:169-175.
Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H,
Levey AI, Lah JJ (2004) Loss of apolipoprotein E receptor LR11 in Alzheimer
disease. Archives of neurology 61:1200-1205.
Schnabel J (2011) Amyloid: little proteins, big clues. Nature 475:S12-14.
Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua
V, Mecocci P, Pani L, Winblad B, Kivipelto M (2014) Clinical trials and latestage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.
Journal of internal medicine 275:251-283.
Schonknecht P, Pantel J, Klinga K, Jensen M, Hartmann T, Salbach B, Schroder J (2001)
Reduced cerebrospinal fluid estradiol levels are associated with increased betaamyloid levels in female patients with Alzheimer's disease. Neuroscience letters
307:122-124.
Selkoe DJ (2011) Alzheimer's disease. Cold Spring Harbor perspectives in biology 3.

110

Selkoe DJ (2012) Preventing Alzheimer's disease. Science 337:1488-1492.
Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, D'Agostino RB (1997)
Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on
risk estimates in the Framingham Study. Neurology 49:1498-1504.
Singh M, Setalo G, Jr., Guan X, Warren M, Toran-Allerand CD (1999) Estrogen-induced
activation of mitogen-activated protein kinase in cerebral cortical explants:
convergence of estrogen and neurotrophin signaling pathways. The Journal of
neuroscience : the official journal of the Society for Neuroscience 19:1179-1188.
Spencer-Segal JL, Tsuda MC, Mattei L, Waters EM, Romeo RD, Milner TA, McEwen
BS, Ogawa S (2012) Estradiol acts via estrogen receptors alpha and beta on
pathways important for synaptic plasticity in the mouse hippocampal formation.
Neuroscience 202:131-146.
Stevens LM, Brown RE (2015) Reference and working memory deficits in the 3xTg-AD
mouse between 2 and 15-months of age: a cross-sectional study. Behavioural
brain research 278:496-505.
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS,
Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and
increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Proceedings of the National Academy of Sciences of the United States of America
90:1977-1981.
Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, Laferla FM (2011)
Inflammation induced by infection potentiates tau pathological features in
transgenic mice. The American journal of pathology 178:2811-2822.
Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (2004) The importance of neuritic
plaques and tangles to the development and evolution of AD. Neurology 62:19841989.
Tohda C, Urano T, Umezaki M, Nemere I, Kuboyama T (2012) Diosgenin is an
exogenous activator of 1,25D(3)-MARRS/Pdia3/ERp57 and improves
Alzheimer's disease pathologies in 5XFAD mice. Scientific reports 2:535.
Tu Y, Wu S, Shi X, Chen K, Wu C (2003) Migfilin and Mig-2 link focal adhesions to
filamin and the actin cytoskeleton and function in cell shape modulation. Cell
113:37-47.
Urano T, Tohda C (2010) Icariin improves memory impairment in Alzheimer's disease
model mice (5xFAD) and attenuates amyloid beta-induced neurite atrophy.
Phytotherapy research : PTR 24:1658-1663.

111

Wahlsten D, Crabbe JC, Dudek BC (2001) Behavioural testing of standard inbred and
5HT(1B) knockout mice: implications of absent corpus callosum. Behavioural
brain research 125:23-32.
Wahlsten D, Metten P, Phillips TJ, Boehm SL, 2nd, Burkhart-Kasch S, Dorow J,
Doerksen S, Downing C, Fogarty J, Rodd-Henricks K, Hen R, McKinnon CS,
Merrill CM, Nolte C, Schalomon M, Schlumbohm JP, Sibert JR, Wenger CD,
Dudek BC, Crabbe JC (2003) Different data from different labs: lessons from
studies of gene-environment interaction. Journal of neurobiology 54:283-311.
Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. Journal of
neurochemistry 101:1172-1184.
Wang Y, Greig NH, Yu QS, Mattson MP (2009) Presenilin-1 mutation impairs
cholinergic modulation of synaptic plasticity and suppresses NMDA currents in
hippocampus slices. Neurobiology of aging 30:1061-1068.
Waring SC, Rosenberg RN (2008) Genome-wide association studies in Alzheimer
disease. Archives of neurology 65:329-334.
Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ (2014) Using mice to
model Alzheimer's dementia: an overview of the clinical disease and the
preclinical behavioral changes in 10 mouse models. Frontiers in genetics 5:88.
Wenk GL (2003) Neuropathologic changes in Alzheimer's disease. The Journal of
clinical psychiatry 64 Suppl 9:7-10.
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982)
Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.
Science 215:1237-1239.
Wilcock GK, Esiri MM, Bowen DM, Smith CC (1982) Alzheimer's disease. Correlation
of cortical choline acetyltransferase activity with the severity of dementia and
histological abnormalities. Journal of the neurological sciences 57:407-417.
Wilson RS, Barral S, Lee JH, Leurgans SE, Foroud TM, Sweet RA, Graff-Radford N,
Bird TD, Mayeux R, Bennett DA (2011) Heritability of different forms of
memory in the Late Onset Alzheimer's Disease Family Study. Journal of
Alzheimer's disease : JAD 23:249-255.
Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, Bolshakov VY, Shen J, Kelleher
RJ, 3rd (2015) Presenilin-1 knockin mice reveal loss-of-function mechanism for
familial Alzheimer's disease. Neuron 85:967-981.
Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR,
Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA,
Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with
Alzheimer's disease beta-secretase activity. Nature 402:533-537.

112

Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of
amyloid beta protein: reversal by tachykinin neuropeptides. Science 250:279-282.
Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, Shen Y,
Li R (2005) Brain estrogen deficiency accelerates Abeta plaque formation in an
Alzheimer's disease animal model. Proceedings of the National Academy of
Sciences of the United States of America 102:19198-19203.
Zahs KR, Ashe KH (2015) More than a FAD: the in vivo effects of disease-linked
presenilin-1 mutations. Neuron 85:893-895.
Zanetti O, Solerte SB, Cantoni F (2009) Life expectancy in Alzheimer's disease (AD).
Archives of gerontology and geriatrics 49 Suppl 1:237-243.
Zhang QG, Wang R, Khan M, Mahesh V, Brann DW (2008) Role of Dickkopf-1, an
antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced
neuroprotection and attenuation of tau phosphorylation. The Journal of
neuroscience : the official journal of the Society for Neuroscience 28:8430-8441.
Zhao LN, Long H, Mu Y, Chew LY (2012) The toxicity of amyloid beta oligomers.
International journal of molecular sciences 13:7303-7327.
Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's
disease and other disorders. Nature reviews Neuroscience 12:723-738.
	
  

113

	
  
Appendix A
TITLE: 5-Choice Serial Reaction Time Task (5-CSRT)
SOP NO.:
DATE:

1.0 INTRODUCTION
The 5-CSRT task has been designed to measure effects of drugs and other manipulations
(ex: genetic) on attentional performance (and stimulus control). The test is performed in a
specially designed touchscreen-based automated chamber with multiple response
locations (’five-windows”) using food reinforcers to maintain performance. The 5CSRTT
is useful for measuring effects of different manipulations on various aspects of attentional
control, including sustained, selective and divided attention – and is relevant to the
definition of neural systems of attention and has applications to human disorders such as
attention deficit/hyperactivity disorder (ADHD) and Alzheimer’s disease.

2.0 EQUIPMENT	
  
- Mouse	
  Touch	
  Screen	
  Systems	
  and	
  ABET	
  II	
  	
  
- 89543CAM	
  	
  5-‐Choice	
  Serial	
  Reaction	
  Time	
  Task	
  with	
  Cambridge	
  Amendment	
  
- 	
  
3.0 PROCEDURE	
  	
  
	
  
3.1 Testing	
  the	
  hardware:	
  
A quick test of the hardware should be done prior to every days training or
testing. To do the hardware testing, follow procedures indicted below:
a. From the main menu the Execution Manager, select the boxes you wish to test.
b. Click the ‘Open/Load Schedule’ icon and select ‘Touch MouseTestLines’ and click
‘Open’.
c. Click the play icon. The boxes are now ready to test.

See Table 1 for Inputs to activate a response and output response expected.

Table 1: Action necessary and output response expected.
Schedule	
  

Inputs	
  to	
  activate	
  (use	
  

Output	
  response	
  

your	
  fingers)	
  
Touch	
  Mouse	
  

Touch	
  Grid	
  1	
  

Test	
  Lines	
  

Image	
  in	
  all	
  grid	
  spaces,	
  Grid	
  1	
  has	
  
30%	
  
of	
  full	
  white,	
  grids	
  2	
  to	
  4	
  have	
  full	
  
white	
  
image.	
  
Activate	
  the	
  Tray	
  to	
  clear	
  all	
  images	
  
and	
  proceed	
  with	
  test.	
  

	
  

Touch	
  Grid	
  2	
  

Image	
  in	
  all	
  grid	
  spaces,	
  Grid	
  2	
  has	
  
40%	
  
of	
  full	
  white,	
  all	
  other	
  grids	
  have	
  full	
  
white	
  image.	
  
Activate	
  the	
  Tray	
  to	
  clear	
  all	
  images	
  
and	
  proceed	
  with	
  test.	
  

	
  

Touch	
  Grid	
  3	
  

Image	
  in	
  all	
  grid	
  spaces,	
  Grid	
  3	
  has	
  
50%	
  
of	
  full	
  white,	
  all	
  other	
  grids	
  have	
  full	
  
white	
  image.	
  

Activate	
  the	
  Tray	
  to	
  clear	
  all	
  images	
  
and	
  proceed	
  with	
  test.	
  
	
  

Touch	
  	
  Grid	
  4	
  

Image	
  in	
  all	
  grid	
  spaces,	
  Grid	
  4	
  has	
  
70%	
  
of	
  full	
  white,	
  all	
  other	
  grids	
  have	
  full	
  
white	
  image.	
  
Activate	
  the	
  Tray	
  to	
  clear	
  all	
  images	
  
and	
  proceed	
  with	
  test.	
  

	
  

Touch	
  	
  Grid	
  5	
  

Full	
  white	
  (bright)	
  image	
  in	
  all	
  grid	
  
spaces.	
  Pulses	
  Sound_On	
  500ms	
  
Activate	
  the	
  Tray	
  to	
  clear	
  all	
  images	
  
and	
  proceed	
  with	
  test.	
  

	
  

Enter	
  the	
  feed-‐tray	
  

House-‐light	
  and	
  tray-‐light	
  illuminate	
  
and	
  	
  feeder	
  -‐	
  800ms	
  

	
  

Exit	
  the	
  feed-‐tray	
  

Houselight	
  and	
  tray	
  light	
  extinguish	
  

	
  

Block	
  Front	
  IR	
  activity	
  

House-‐light	
  illuminates	
  

beams	
  
	
  

Block	
  Back	
  IR	
  activity	
  
beams	
  

3.2 Testing	
  the	
  feeder	
  and	
  mask	
  

Tray-‐light	
  illuminates	
  

A	
   quick	
   test	
   of	
   the	
   feeder	
   should	
   be	
   done	
   prior	
   to	
   every	
   days	
   training	
   or	
  
testing.	
  That	
  is,	
  turn	
  on	
  manually	
  the	
  switch	
  on	
  the	
  feeder	
  pump	
  and	
  make	
  
sure	
  the	
  food	
  is	
  delivered.	
  	
  
- Make	
  sure	
  the	
  5CSRT	
  Mask	
  is	
  inserted	
  (5	
  windows).	
  
- Reward	
  provided	
  is	
  Neilson	
  Strawberry	
  milkshake	
  (SM)	
  (Saputo	
  Inc.	
  Montreal	
  
Quebec.	
   H1P1X8).	
   This	
   milkshake	
   can	
   be	
   found	
   in	
   most	
   grocery	
   stores	
  
(including	
  Wall	
  Mart	
  and	
  Superstore).	
  
	
  
3.3 Pre-‐training	
  
Animals	
  need	
  to	
  be	
  food	
  restricted	
  before	
  task	
  training	
  and	
  throughout	
  
experiment	
  (see	
  relevant	
  SOPs:	
  “Food	
  restriction	
  in	
  young	
  mice”	
  or	
  “Food	
  
restriction	
  in	
  adult	
  mice”).	
  	
  
Divide	
  the	
  subjects	
  of	
  each	
  group	
  to	
  be	
  tested	
  (Ex:	
  Group	
  1:	
  5xFAD	
  females,	
  
Group	
  2:	
  APP	
  males)	
  into	
  4	
  sub-‐groups	
  (A,	
  B,	
  C,	
  D).	
  Groups	
  must	
  be	
  counter-‐
balanced	
  for	
  genotype	
  (wt	
  x	
  mutant).	
  Each	
  subgroup	
  is	
  going	
  to	
  follow	
  specific	
  
testing	
  schedules	
  during	
  probe	
  trial	
  (see	
  Table	
  2).	
  
-

-

-

3.4 Training	
  Procedures	
  
	
  
3.4.1 Basic	
  training	
  schedule	
  	
  

IMPORTANT: for both training and probe trials, each mouse is submitted to one session
per day.

Stage 1: Habituation1: 1 session. Load the habituation1 schedule from the CAM5choice subdirectory in the ABETII software. The session duration is set to 600s (10
minutes), and the number of trials is left to unlimited. Mouse is left in the chamber for 10
min. All lights are turned off. No stimulus or reward is presented. It is critical that the
mouse is removed from the cabinet as soon as the habituation is complete.

Stage 2: Habituation2a: 2 sessions. Load the habituation2 schedule from the CAM5choice subdirectory in the ABETII software. The session duration is set to 1200s (20
minutes), and the number of trials is left to unlimited. The mouse is left in the chamber
for 20 min sessions. The tray light is going to be initially turned on. A tone is played and
the food-tray/magazine is primed with strawberry milkshake (SM) delivered for 6000ms
(150µl). The program waits for the mouse to enter the food tray. When the mouse leaves
the reward tray, the reward tray light is turned off. There is a 10s delay before the tray
light is turned on, a tone is played and SM is then delivered for 280ms (7 µl). If the

mouse is in the reward tray at the end of the 10s delay, an extra 1s is added to the delay.
The procedure is repeated until the session ends.

Stage 3: Habituation2b: 1 session. Load the habituation2 schedule from the CAM5choice subdirectory in the ABETII software. The session duration is set to 2400s (40
minutes), and the number of trials is left to unlimited. The mouse is left in the chamber
for 40 min. Reward presentation is the same as described in stage 2. It is critical that the
mouse is removed from the cabinet as soon as the habituation is complete.

Stage 4: “Initial touch”: (usually 1 session). Load the schedule ‘5-choice Mouse Initial
Touch Training’ from the CAM-5choice subdirectory. Set the Session:
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure
that “Image Time” is 30s; ‘Feed Pulse Time” is 280ms; “tone duration” is 1000 ms, and
ITI period is 5s. The stimulus (a white square) is displayed randomly in one of the 5
windows. The stimulus is presented in only one window at a time. The other windows are
left blank. The position is chosen pseudo randomly, such that the stimulus will not be
displayed in the same position more than 3 times in a row. After a delay (Image Time –
30s) the image is removed and food is delivered (‘Feed Pulse Time –280ms). Food
delivery is accompanied by illumination of the tray light and a tone. The tone frequency
is 3 KHz. The tone duration is (1000 ms). Entry to collect the food turns off the tray light
and starts the ITI. After the ITI period (5s) another image is displayed. If the mouse
touches the screen whilst the image is displayed (where the image is displayed), the
image is removed, a tone will be played and 3 x food is delivered immediately.
Collection of this reward again starts the ITI and then progresses to the next image.
Touch training is performed with the house light off.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.

Stage 5: “Must touch”: Number of session varies for individual mouse. It can go from
~1-7 days (median: 2 days). Run the schedule ‘5-choice Mouse Must Touch Training’
from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to 60
minutes, i.e. 60:00. Set the Max No Trials to 30. Make sure tone duration is set to 1000
ms (from the ‘Tone Duration’ variable) and ITI period is set to 5s.
The stimulus (a white square) is displayed randomly in one of the 5 windows. The
stimulus is presented in only one window at a time. The other windows are left blank.
The position is chosen pseudo randomly, such that the stimulus will not be displayed in
the same position more than 3 times in a row. The mouse must touch the stimulus to elicit
tone/food response. There is no response if mouse touches blank part of the screen. Food
delivery is accompanied by illumination of the tray light and a tone. The tone frequency

default is 3 KHz. Entry to collect the food turns off the tray light and starts the ITI. After
the ITI period (5s) another image is displayed.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.
IMPORTANT: If after 7 sessions a mouse does not reach criterion for “must touch”,
take it back one step; that is, retrain the mouse on “Initial touch” until it reaches criterion
and repeat the “Must touch” training. If after 7 sessions of the second attempt of “must
touch” the mouse does not reach criterion, remove it from the study.
Stage 6: “Must initiate”: Number of session varies for individual mouse. It usually
takes ~1-2 sessions (i.e. 1 or days). Run the schedule ‘5-Choice Must Initiate Training’
from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to 60
minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure tone duration is set to 1000
ms (from the ‘Tone Duration’ variable) and ITI period is set to 5s.
A free delivery of food is made and the tray light is turned on. The mouse must nose poke
and exit the reward tray before a stimulus is displayed randomly on the screen. The
stimulus (a white square) is displayed randomly in one of the 5 windows. The stimulus is
presented in only one window at a time. The other windows are left blank. The position is
chosen pseudo randomly, such that the stimulus will not be displayed in the same
position more than 3 times in a row.) The mouse must touch the stimulus to elicit
tone/food response. There is no response if mouse touches the blank parts of the screen.
Food delivery is accompanied by illumination of the tray light and a tone. Entry to collect
the food turns off the tray light and starts the ITI. After the ITI period the tray light is
again illuminated. The mouse must nose poke and exit the reward tray before the next
image is displayed.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.
IMPORTANT: If after 5 sessions a mouse does not reach criterion for “must initiate”,
take it back one step; that is, retrain the mouse on “must touch” until it reaches criterion
and repeat the “Must Initiate” training. If after 5 sessions of the second attempt of “must
initiate” the mouse does not reach criterion, remove it from the study.
Stage 7: “Punish incorrect”. Number of session varies for individual mouse. It can go
from ~2-30 days (median: 9 days). Run the schedule ‘5-Choice Mouse Punish Incorrect
Training’ from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to
60 minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure tone duration is set to
1000 ms and ITI period is set to 5s.

This schedule trains the mouse to both initiate after an ITI and not to touch an incorrect
location. As for previous training described above, except if a mouse touches an incorrect
(non-illuminated) location the house light will be turned ON for 5s and no reward is
given. Once the time out period finishes the house light is turned OFF again and the ITI
period begins (5s). The mouse must then complete a correction trial: the image and
position from the previous trial are kept the same and the mouse must repeat the same
trial until a correct response to the image is made, at which point it will receive a tone
and reward.
Criterion: Completion of 23/30 trials or better within 60 min for 2 consecutive sessions
IMPORTANT: If after 30 sessions (30 days) the mouse does not reach criterion for
“Punish incorrect”, remove it from study.
3.4.2 5-‐CSRT	
  Training	
  to	
  baseline	
  
Stage 8: 5-CSRT training to baseline- 4s stimulus. Number of session varies for
individual mouse. It can go from ~4-30 days (median: 11 days). Run the
‘5CSRTT_4s_Var1’ from the CAM-5choice subdirectory schedule. Set the Session:
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 50. Make sure
tone duration is set to 1000 ms, ITI period is set to 5s, Food/CM pulse time [280ms (7 µl
SM), Delay interval (5s), time out (TO, 5s) and ITI Incorr (5s).

The session begins with a priming delivery of reinforcer [280ms (7 µl SM)] and on
exiting the food magazine the first trial begins. Following tray exit, a “Delay interval”
(5s) begins at the end of which a stimuli is presented in one of the 5 stimuli grid spaces
on the LCD touch screen. The sequence of presentations of the stimuli is a pseudorandom
schedule such that there are 4 presentations at each spatial location within a block of 20
trials. The subject must respond within a time period defined (limited hold period 5s). A
correct response, touching at the location in which the stimulus was presented, will
trigger the presentation of reinforcer [280ms (7 µl SM)] into the food magazine. Food
delivery is accompanied by illumination of the tray light and a tone. The tone duration is
(1000 ms tone). The subject collects the food by making an entry at the food magazine.
On exiting the food tray the ITI (5s) will begin. After the ITI period, the tray light comes
on again and the mouse must enter and exit the food tray to start the next trial and start
the Delay’ interval. An incorrect response, i.e. touching a location other than where the
stimulus was presented, or making no response at all (an omission) within the limited
hold period, will cause a time out (TO, 5s) as identified house light turned ON. After the
TO, the house light will be turned OFF and the “ITI Incorr” will begin (5s). After the
ITI incorr period the tray light will come on and the subject must enter and exit the food
tray to start the next trial and start the Delay’ interval. A premature response is recorded
when a touch is made in one of the response grid areas during the Delay and also results
in a TO.

> 80% accuracy = [number of Correct trials / Total number of trials responded to (correct
and incorrect)]
< 20% omissions = [number of trials missed / number of trials presented]

Criterion: 80% accuracy or better, 20% omission or less, 3 consecutive days, minimum
30 trials completed per session.

Stage 9: 5-CSRT training to baseline- 2s stimulus. Number of sessions varies for
individual mouse. It can go from ~5-30 days (median: 12 days). Run the
‘5CSRTT_2s_Var1 schedule from the CAM-5choice subdirectory. Set the Session:
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 50. . Make sure
tone duration is set to 1000 ms, ITI period is set to 5s, Food/CM pulse time [280ms (7 µl
SM), Delay interval (5s), time out (TO, 5s) and ITI Incorr (5s).
The session begins with a priming delivery of reinforce [280ms (7 µl SM)] and on
exiting the food magazine the first trial begins. Following tray exit, a “Delay interval”
(5s) begins at the end of which a stimuli is presented in one of the 5 stimuli grid spaces
on the LCD touch screen. The sequence of presentations of the stimuli is a pseudorandom
schedule such that there are 4 presentations at each spatial location within a block of 20
trials. The subject must respond within a time period defined (limited hold period 5s). A
correct response, touching at the location in which the stimulus was presented, will
trigger the presentation of reinforce [280ms (7 µl SM)] into the food magazine. Food
delivery is accompanied by illumination of the tray light and a tone. The tone duration is
(1000 ms tone). The subject collects the food by making an entry at the food magazine.
On exiting the food tray the ITI (5s) will begin. After the ITI period, the tray light comes
on again and the mouse must enter and exit the food tray to start the next trial and start
the Delay’ interval. An incorrect response, i.e. touching a location other than where the
stimulus was presented, or making no response at all (an omission) within the limited
hold period, will cause a time out (TO, 5s) as identified house light turned ON. After the
TO, the house light will be turned OFF and the ‘ITI Incorr’ will begin (5s). After the ITI
incorr period the tray light will come on and the subject must enter and exit the food tray
to start the next trial and start the Delay’ interval. A premature response is recorded when
a touch is made in one of the response grid areas during the Delay and also results in a
TO.
Criterion: 80% accuracy or better, 20% omission or less, 3 consecutive days, 50 trials
must be completed per session.

3.4.3 Testing	
  schedules	
  

Stage 10: First probe trial evaluation. Subjects will not progress through the training at
exactly the same rate. The first set of probe trials for a group begins once the last mouse
in that group has passed the 2s stimulus performance criteria (Stage 9). Subjects that have
completed the Stage 9 before the slowest subject are maintained on food restriction and
repeat Stage 9 before performing their probe trial. There is no minimum performance
criterion for subjects to advance through the probe trials. The order of performance of
probe trials for each counter-balanced group varies according to Table 2.
-

-

-

-

-

For	
  the	
  2s	
  stimulus	
  run	
  the	
  ‘5CSRTT_2s_Var1schedule	
  from	
  the	
  CAM-‐5choice	
  	
  
subdirectory.	
  Set	
  the	
  Session:	
  Max_Schedule_Time	
  to	
  60	
  minutes,	
  i.e.	
  60:00.	
  Set	
  
the	
  Max	
  No.	
  Trials	
  to	
  50.	
  
For	
  the	
  1.5s	
  stimulus	
  run	
  the	
  ‘5CSRTT_1.5s_Var1schedule	
  from	
  the	
  CAM-‐5choice	
  
subdirectory.	
  Set	
  the	
  Session:	
  Max_Schedule_Time	
  to	
  60	
  minutes,	
  i.e.	
  60:00.	
  Set	
  
the	
  Max	
  No.	
  Trials	
  to	
  50.	
  
For	
  the	
  1s	
  stimulus	
  run	
  the	
  ‘5CSRTT_1s_Var1schedule	
  from	
  the	
  CAM-‐5choice	
  	
  
subdirectory.	
  Set	
  the	
  Session:	
  Max_Schedule_Time	
  to	
  60	
  minutes,	
  i.e.	
  60:00.	
  Set	
  
the	
  Max	
  No.	
  Trials	
  to	
  50.	
  
For	
  the	
  	
  0.8s	
  stimulus	
  run	
  the	
  ‘5CSRTT_0.8s_Var1schedule	
  from	
  the	
  CAM-‐5choice	
  	
  
subdirectory.	
  Set	
  the	
  Session:	
  Max_Schedule_Time	
  to	
  60	
  minutes,	
  i.e.	
  60:00.	
  Set	
  
the	
  Max	
  No.	
  Trials	
  to	
  50.	
  
For	
  the	
  	
  0.6s	
  stimulus	
  run	
  the	
  ‘5CSRTT_0.6s_Var1schedule	
  from	
  the	
  CAM-‐5choice	
  	
  
subdirectory.	
  Set	
  the	
  Session:	
  Max_Schedule_Time	
  to	
  60	
  minutes,	
  i.e.	
  60:00.	
  Set	
  
the	
  Max	
  No.	
  Trials	
  to	
  50.	
  

Table 2: Order of stimulus duration for individual groups (1st probe trial
evaluation)
#	
  of	
  

Stimulus	
  

Stimulus	
  

Stimulus	
  

Stimulus	
  

consecutive	
  

duration	
  

duration	
  

duration	
  

duration	
  

sessions	
  

throughout	
  	
  

throughout	
  	
  

throughout	
  	
  

throughout	
  	
  

sessions	
  for	
  	
  

sessions	
  for	
  	
  

sessions	
  for	
  	
  

sessions	
  for	
  	
  

Sub-‐group	
  A	
  

Sub-‐group	
  B	
  

Sub-‐group	
  C	
  

Sub-‐group	
  D	
  

2	
  

0.6s	
  

0.8s	
  

1.0s	
  

1.5s	
  

2	
  

2.0s	
  

2.0s	
  

2.0s	
  

2.0s	
  

2	
  

1.5s	
  

0.6s	
  

0.8s	
  

1.0s	
  

2	
  

2.0s	
  

2.0s	
  

2.0s	
  

2.0s	
  

2	
  

1.0s	
  

1.5s	
  

0.6s	
  

0.8s	
  

2	
  

2.0s	
  

2.0s	
  

2.0s	
  

2.0s	
  

2	
  

0.8s	
  

1.0s	
  

1.5s	
  

0.6s	
  

Table 3: Setting adjustment for additional variables in probe trials
Variable	
  

Value	
  

Session	
  Length	
  

60	
  min	
  

Food/CM	
  pulse	
  time	
  

280	
  ms	
  

DELAY	
  

5s	
  

Time	
  out	
  

5s	
  

Limited	
  Hold	
  Value	
  

	
  5s	
  

Stage 11: Reusing same mouse cohort for a new probe trial
- All subjects are maintained on food restriction for 1 month.

- Subjects perform one 2s stimulus trial per week during the interval between probe trials.

Stage 12: Second probe trial evaluation

-

Mice should be re-baselined at 2s (Stage 9: >80% Accuracy, <20%
omissions). Depending on how long it’s been since the previous probe trial it
might be necessary to rebaseline them at 4s first (Stage 8). If they are not rebaselined the second probe trial will not be accurate.

-

A	
   second	
   probe	
   trial	
   should	
   be	
   performed	
   according	
   to	
   the	
   order	
   shown	
   in	
  
Table	
  4.	
  	
  

Table 4: Order of stimulus duration for individual groups (2nd probe trial
evaluation)
#	
  of	
  

Stimulus	
  

Stimulus	
  

Stimulus	
  

Stimulus	
  

consecutive	
  

duration	
  

duration	
  

duration	
  

duration	
  

sessions	
  

throughout	
  	
  

throughout	
  	
  

throughout	
  	
  

throughout	
  	
  

sessions	
  for	
  	
  

sessions	
  for	
  	
  

sessions	
  for	
  	
  

sessions	
  for	
  	
  

Sub-‐group	
  A	
  

Sub-‐group	
  B	
  

Sub-‐group	
  C	
  

Sub-‐group	
  D	
  

2	
  

1.5s	
  

0.6s	
  

0.8s	
  

1.0s	
  

2	
  

2.0s	
  

2.0s	
  

2.0s	
  

2.0s	
  

2	
  

1.0s	
  

1.5s	
  

0.6s	
  

0.8s	
  

2	
  

2.0s	
  

2.0s	
  

2.0s	
  

2.0s	
  

2	
  

0.8s	
  

1.0s	
  

1.5s	
  

0.6s	
  

2	
  

2.0s	
  

2.0s	
  

2.0s	
  

2.0s	
  

2	
  

0.6s	
  

0.8s	
  

1.0s	
  

1.5s	
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